Vasopressin

“ 点击蓝字 关注我们 蛋白及多肽类药物口服递送策略的研究现状及思考 PPS  贾蓓 1，2#，高铎 1#，吴佳淇 1，袁瑞 1，郭仕艳 1，甘勇 1，2* （1. 中国科学院上海药物研究所，上海 201210；2. 沈阳药科大学药学院，辽宁 沈阳 110016） 甘勇 中国科学院上海药物研究所课题组长、研究员、博士生导师，国家自然科学基金青年科学基金项目 （A类） 获得者。兼任国家药典委员会委员、国家药品审评中心评审专家、中国药学会工业药剂专业委员会及药用辅料专业委员会委员，同时担任 Acta Pharm Sin B、Asian J Pharm Sci、Chin ChemLett、Chin Med等期刊编委。作为项目负责人，主持国家重点研发计划项目、国家自然科学基金重点项目等多项国家级课题。 主要科研方向为新型药物载体制剂理性设计及克服复杂生理屏障机制研究。在 Sci Transl Med、Nat Nanotechnol和PNAS等国内外期刊上发表研究论文100余篇。带领团队积极开展创新制剂转化研究，累计获授权发明专利45项、新药临床试验批件18项，研发上市创新制剂8项。先后获评科技部中青年创新领军人才、中国药学会-以岭生物医药青年奖、上海市科技系统工匠等荣誉。 [摘要]蛋白及多肽类药物具有较高的靶点选择性和生物活性，已广泛应用于糖尿病、肿瘤等重大疾病的临床治疗；但该类药物口服生物利用度普遍低于 1%，临床给药方式仍以注射途径为主。近年来，口服递送技术为蛋白及多肽类药物实现非侵入给药提供了可行路径；然而，不同蛋白及多肽类药物口服给药的主要限制因素存在差异，常随药物的分子特征及吸收、分布和清除等体内处置过程发生改变。仅针对单一吸收屏障进行工艺优化，难以稳定提升且精准调控口服生物利用度。综述从吸收、分布和清除 3 个环节解析口服蛋白及多肽类药物的体内行为，总结归纳其口服吸收效率受限的内在机制，明确不同递送策略的适用范围与作用条件，以期为蛋白及多肽类药物口服制剂的理性设计及临床转化研究提供理论参考。 自 1921 年胰岛素首次应用于临床以来，蛋白及多肽类药物因具有靶点选择性强、生物活性高等特性，已在糖尿病、恶性肿瘤及自身免疫病等疾病领域得到成功治疗应用，目前全球获批上市的该类药物已接近 100 种[1-2]。但该类药物口服生物利用度普遍低于 1%，临床给药途径仍以注射给药为主。尽管现有研究已开发结构修饰、渗透增强及载体设计等多种口服递送手段并已在体外实验及动物模型中取得重要进展，但整体临床转化速度仍显缓慢。对目前已公开的口服蛋白及多肽类药物临床试验数据进行系统梳理可知，截至 2026 年，相关临床研究累计超 170 项，但仅有 6 项进入Ⅲ期临床试验阶段[3]。这一转化数据表明，口服蛋白及多肽类药物递送系统研发受阻并非单一技术因素所致，更有可能与体内复杂生理屏障共同作用相关。 以往研究多根据胃肠道解剖结构，将口服递送屏障划分为腔内降解、黏液阻滞及上皮转运受阻等独立环节，并针对不同屏障分别进行优化。这种基于结构层级的分析模式能够很好阐释单一屏障对递送效率的影响，但易固化“优先攻克某一关键屏障即可突破递送局限”的研究思路。现有实验数据证实，不同蛋白及多肽类药物口服后全身暴露受限并非固定发生于单一环节，而是呈现明确的序贯性限制特征：部分药物在胃肠道腔内即快速降解；部分药物主要受肠道上皮跨膜转运效率的限制；还有部分药物即便进入体循环，也会因血浆蛋白结合、肝脏代谢或肾脏排泄等过程而无法维持有效血药浓度，难以稳定发挥药理作用[4-5]。因此，口服蛋白及多肽类药物的体内作用效果遵循药物体内过程逐级损耗的序贯性变化规律，并非仅受单一生理屏障调控。基于此，本文从药物体内处置过程出发，将蛋白及多肽类药物口服递送过程划分为吸收、分布和清除3 个连续阶段，对比不同药物在各阶段的主要制约因素，梳理代表性基础研究成果与临床转化实际成效，总结不同递送策略的适用范围和作用条件，以期为口服蛋白及多肽类药物制剂的理性设计和临床转化提供参考。 1 影响蛋白及多肽类药物口服递送中的分子属性及体内受限环节 1.1 影响蛋白及多肽类药物口服递送的关键分子属性 蛋白及多肽类药物口服后全身暴露水平主要取决于其自身分子属性与体内吸收、分布及清除序贯性生理环节的适配程度。与小分子药物不同，蛋白及多肽类药物的生物活性依赖于三维空间结构的完整性和稳定性，其在胃肠环境中的稳定性、界面行为及体内处置特征等均依赖于其自身分子属性。其中，分子量是决定该类药物突破胃肠道生理屏障能力的关键属性。随着分子量的增加，药物在肠道黏液层的扩散阻力显著增加，且其跨膜转运方式逐渐由被动扩散转变为转运效率较低的胞吞或跨细胞转运。分子量约 1 000 的去氨加压素具有较好的黏液层扩散能力，而分子量约 6 000 的胰岛素黏液层扩散效率明显下降；分子量更大的生长激素 （约 22 000）或单克隆抗体 （约 150 000） 的转运过程则明显受阻[6]。由此可见，分子量可通过调控蛋白及多肽类药物的跨黏液和跨胞转运途径，直接决定其能否到达吸收界面并发挥药理作用。 除分子量外，分子结构特征直接影响蛋白及多肽类药物在起效部位的作用效果及滞留时间。该类药物在胃酸、消化酶的作用下易发生空间结构改变，暴露自身酶切位点并与消化酶发生相互作用，进而加快药物降解速度。在 pH 低于 3 的强酸性胃肠环境中，胰岛素的 α-螺旋结构被快速破坏，30 min内药物结构完整率降低至 1% 以下[7]。结构高度受限的环肽类药物可通过空间结构屏蔽其自身酶切位点，在胃肠道内表现出更佳的结构稳定性。同时，分子电荷及亲疏水属性可调控蛋白及多肽类药物在体内不同界面中的行为变化。肠道黏液层内，部分抗菌肽等药物自身所带正电或疏水暴露区域易与黏液层中带负电的糖链发生非特异性结合，使其扩散速率下降 2 ~ 3 个数量级[2]。采用亲水化修饰策略可减少蛋白及多肽类药物在黏液层的吸附与留问题，但过度亲水化会影响其与细胞膜的相互作用，降低跨胞转运效率。此外，上述分子属性可进一步调控蛋白及多肽类药物入血后的分布与清除行为。经脂肪酸修饰的司美格鲁肽在血浆中与白蛋白发生高亲和力结合，以结合物的形式将其半衰期延长至7 d；而奥曲肽入血后约 60% 的药物以结合物的形式存在，加快肾脏对药物的清除速率[8-9]。总体来说，蛋白及多肽类药物的各类分子属性通过协同参与并调控吸收、分布及清除的序贯性生理环节，共同决定药物的体内处置命运及全身暴露水平。 1.2 不同类型蛋白及多肽类药物的体内关键受限环节 基于口服吸收过程对蛋白及多肽类药物进行分类，有助于厘清不同药物全身暴露受限的本质差异，为其选择合适递送策略提供理论依据。根据体内主要受限环节，可将蛋白及多肽类药物分为吸收受限、分布受限及清除受限 3 类（见图 1），受限机制分别对应胃肠道降解及跨膜转运不足、起效部位分布限制、体内清除效率过高。其中，吸收受限型药物最为典型。多数该类药物受胃肠道腔内环境影响较大，如胰岛素在胃肠道酸性环境及大量水解酶的共同作用下快速降解，真正到达肠道吸收界面的有效药物浓度极低[3]；同时，部分药物具有较强的水溶性，易受到界面转运效率的影响，如去氨加压素在黏液层中的迁移能力和上皮跨膜转运效率均较低，且在细胞内经内体-溶酶体途径进一步降解失活，最终口服生物利用度仅为 0.08% ~ 0.16%，全身暴露水平极低[4]。 部分药物突破胃肠道吸收屏障进入体循环后，其递送限制因素则由吸收环节转向分布与清除环节。蛋白及多肽类药物独特的三维空间结构使其易与血浆中多种蛋白发生非特异性结合，降低体内游离药物浓度，干扰药物在作用部位的分布及全身暴露水平。与此同时，酶促降解、肝脏代谢、肾脏排泄及网状内皮系统摄取等清除机制可快速降低血浆中药物 浓 度 ， 如 胰 高 血 糖 素 样 肽 -1 （glucagon-like peptide-1，GLP-1）类药物分子尺寸低于肾小球滤过阈值 （分子量 50 000~70 000），可经肾小球快速滤过清除[10]。然而，部分药物的作用靶点位于肠腔或黏膜局部，其口服递送并不以提高全身暴露水平为目标，制剂设计重点在于维持局部区域的药物浓度和滞留时间。总体来看，不同类型蛋白及多肽类药物的关键受限屏障差异较大，这也是相同递送策略对不同药物临床转化效果存在差异的主要原因，为后续阐明吸收、分布及清除序贯性生理屏障机制提供逻辑支撑。 2 影响蛋白及多肽类药物体内全身暴露的生理屏障 2.1 吸收屏障 蛋白及多肽类药物口服后的吸收受限是胃肠道连续生理环境共同作用的结果，主要涵盖腔道降解、黏液阻滞与上皮细胞转运受限 3 个方面 （见图 1）。在胃肠腔道中，药物首先暴露于强酸性介质及大量蛋白酶体系中。胃内强酸可迅速破坏该类药物的空间立体结构，胰岛素在模拟胃液中孵育 30 min，结构完整率降至 1% 以下[3]。随后，胃蛋白酶优先切割药物暴露的肽键，进入小肠后，胰蛋白酶、糜蛋白酶及弹性蛋白酶持续分解药物，肠道刷状缘肽酶完成最终酶解切割，导致多数药物尚未到达吸收位点便发生降解。因此，胃肠道腔内的药物降解程度直接决定了药物全身暴露的最大理论值，采用肠溶包衣等制剂策略可有效规避吸收阶段的药物降解损耗。药物耐受胃肠道酶解环境进入肠腔后，将面临肠道黏液层屏障。该层厚度为 25 ~ 200 μm，主要由杯状细胞分泌的黏蛋白 2 构成，通过共价与非共价作用交联形成具有黏弹性的网络结构[11]。这一结构显著阻滞蛋白及多肽类药物及纳米颗粒等外源物质的被动扩散，延缓药物迁移进程。药物的自身正电荷及疏水区域易与黏液层组分发生非特异性结合，进而降低其有效转运效率[12]。同时，肠道黏液层以2~3 h 的周期持续更新，药物需在极短时间窗口期内穿透黏液层，否则将随黏液更新被清除，难以完成后续吸收过程。 此外，蛋白及多肽类药物主要通过胞吞或跨胞转运的方式穿透肠道上皮细胞，而该过程往往伴随大量药物损耗。上皮细胞内体成熟过程中，腔内 pH值逐渐下降，激活多种水解蛋白酶，导致入胞后的药物在转运至细胞基底侧前即被降解。研究表明，胰岛素入胞后仅 5% 能够以完整结构到达细胞基底侧[13]。这一现象也解释了体外渗透实验的结果与体内吸收效果存在偏差的原因，即口服吸收的关键并非药物能否进入上皮细胞，而是其能否有效规避胞内降解，并顺利转运至细胞基底侧实现高效吸收。 2.2 分布屏障 药物分布是指药物入血后向机体各组织转运并达到动态平衡的过程，直接决定药物的组织浓度、作用部位及持续作用时长。口服蛋白及多肽类药物本身全身暴露水平较低，受胃肠道降解、跨生理屏障转运困难等因素影响，分布过程对其体内有效药物浓度的制约作用进一步放大，成为限制药物全身暴露的重要屏障。蛋白及多肽类药物及其递送载体进入血液循环后，在较短时间内与血浆白蛋白、脂蛋白及免疫球蛋白等组分结合，形成动态蛋白冠（见图 1），改变药物的体内存在形式。常规分布评价多检测血浆总药物含量，而真实的体内暴露与药效评估则需以发挥药理作用的游离药物浓度及有效到达作用部位的药物占比为依据[14]。相关研究表明，奥曲肽入血后约 60% 与血浆蛋白结合，以结合态存在的药物无法有效结合生长抑素受体，药理作用受到明显抑制[15]。线性阳离子抗菌肽 LL-37 在血浆中超过 90% 以非特异性蛋白结合的形式存在，造成感染部位有效药物供给不足、起效延迟[16]。蛋白冠的组成并非固定不变，其随药物表面性质及其所处血液环境动态变化发生改变。未经结构修饰的蛋白及多肽类药物更易暴露其表面的电荷及疏水残基，从而被补体蛋白或免疫球蛋白识别，进而触发单核吞噬系统的摄取与清除，表现为该类药物的循环半衰期明显缩短。对蛋白及多肽类药物进行聚乙二醇（polyethylene glycol，PEG） 化或脂肪酸化等修饰，可有效调控该类药物的蛋白冠组成，通过增加空间位阻、促进白蛋白等蛋白的特异性吸附，降低机体对药物的非特异性识别与清除效率[17]。因此，评价蛋白及多肽类药物的口服分布过程不应仅关注其是否入血，更应关注其入血后能否维持足够的游离药物浓度并有效富集于作用部位。 2.3 清除屏障 蛋白及多肽类药物经胃肠道吸收进入体循环后，其全身暴露会持续受到多重有序清除机制的调控，主要包括酶促降解、肝脏代谢、肾脏排泄及网状内皮系统摄取等（见图 1）。口服给药本身形成的药物全身暴露水平较低，上述清除效应会被进一步放大[18]。肝脏是药物进入体循环后发生代谢和摄取清除最活跃且重要的器官之一，药物进入肝窦后，可同时被库普弗细胞和肝实质细胞摄取、降解及代谢。库普弗细胞占肝脏非实质细胞总量的 20% ~ 25%，可通过清道夫受体等途径高效识别并摄取外源性药物及其递送载体，最终在溶酶体中予以降解。肝实质细胞可通过受体介导摄取、胞内蛋白水解或代谢酶催化等不同方式破坏药物的结构完整性，从而降低其受体结合能力。因此，肝脏不仅参与药物入血初期的清除过程，而且在后续的循环中持续介导其代谢与降解，是影响药物全身暴露的重要清除器官[19]。 肾脏排泄是调控蛋白及多肽类药物体内暴露的另一重要且可量化的途径，其清除效率与药物分子量、空间构象、血浆蛋白结合率及降解片段尺寸直接相关。一般而言，分子量低于肾小球滤过阈值的药物及其降解片段，更易经肾小球滤过途径清除；分子量较大或与血浆蛋白结合率较高的药物，肾清除速率相对缓慢[20]。例如 GLP‑1 类药物分子量仅3 000 ~ 4 000，明显低于肾小球滤过阈值，故其极易经肾小球滤过并被快速清除。除肝肾清除途径外，网状内皮系统也参与了药物及其递送载体的清除过程。巨噬细胞表面的清道夫受体、Fc 受体或补体相关受体均可识别外源性蛋白及多肽类药物或其表面形成蛋白冠的递送颗粒，进而介导药物的胞内摄取与降解清除。此外，部分环肽、脂肪酸化修饰多肽或胆汁酸类递送体系还可通过肝胆途径排泄，进一步增加了药物体内清除路径的复杂性。总体而言，蛋白及多肽类药物的体内清除并非单一器官或单一途径独立作用的结果，而是肝脏摄取代谢、肾脏排泄以及网状内皮系统清除等多途径协同作用所致。在口服给药低水平全身暴露的背景下，多重清除过程会进一步加剧有效药物浓度的下降，导致进入体循环的药物难以维持稳定的体内暴露水平。 2.4 常用体内外口服评价模型 目前用于蛋白及多肽类药物口服递送效果的评价模型主要分为体外、离体和体内 3 类。以往常采用单一模型或 2 种模型联用开展药效及递送效果评价，但往往难以完整模拟体内从吸收、分布到清除的序贯性屏障过程。体外模型主要包括胃肠液模拟系统、黏液穿透装置、Caco-2 细胞单层模型等，适用于药物口服递送系统的快速筛选，但该类模型无法还原胃肠排空、黏液更新及体内系统清除等动态生理过程，测得的药物吸收参数常被高估。外翻肠囊、尤斯灌流等离体模型可在一定程度上保留肠道组织结构与生理功能，但普遍存在组织存活时间短、实验重复性差等局限[21]。蛋白及多肽类药物血浆蛋白结合率的常规检测下限为微摩尔级，但药物口服给药入血后的有效浓度仅为纳摩尔级，结合位点未达到饱和状态，导致检测结果与实际体内结合水平存在明显偏差[22]。动物体内模型可实现药物吸收、分布和清除的序贯性屏障过程，但评价结果易受种属差异干扰。其中，啮齿类动物胃肠排空速率、肠道酶谱等与人体差异较大，动物模型测得的实验结果往往比人体实际值偏高 30% ~ 40%，相关实验数据需结合大动物或人体药代动力学数据进行谨慎外推计算[23]。 目前，许多研究仅单独验证药物腔道稳定性、黏液穿透能力和跨膜转运效率等单一环节，但药物的口服递送本质上是序贯性生理屏障共同作用的动态过程，对单一环节的优化无法等同于药物整体全身暴露水平的提升。单独评估局部递送过程难以直观反映药物完整的体内处置行为，这也是当前体外实验结果与体内药代动力学数据相关性较差的主要原因。因此，更科学的评价体系应采用序贯性验证思路，依次考察药物胃肠稳定性、黏液穿透性能、上皮转运效率、血浆蛋白结合特性、体内药代动力学/药效动力学（pharmacokinetics / pharmacodynamics ，PK/PD） 特征及生物安全性等，并在此基础上综合考量不同动物模型与人体在胃肠生理环境、酶系表达和转运蛋白功能等方面的种属差异，以此提升体内外评价结果的准确性，精准预判蛋白及多肽类药物口服递送的体内表现及临床应用前景。 3 针对关键受限环节的递送策略与设计原则 蛋白及多肽类药物口服后的全身暴露水平由吸收、分布和清除 3 个连续的体内处置过程共同调控。早期研究大多聚焦于吸收阶段，重点在于提升药物分子胃肠道稳定性、增强跨屏障转运能力，以提高进入体循环的药物占比。随着载体递送技术发展，研究范围逐渐延伸至药物入血后的处置过程，将分布和清除环节纳入制剂设计的考量范畴。从现有研究思路分析，口服递送策略可大致分为 2 类：一类延续传统研究思路，专注改善吸收以提升入血药量；另一类借助载体的理性设计，同步调控吸收、分布、清除全过程，实现对药物全身暴露的整体性干预（见图 2）。 3.1 针对吸收受限环节的递送策略 蛋白及多肽类药物口服吸收效率低，主要受 2类生理因素制约。其一，胃肠道酸性环境和多种蛋白水解酶可持续降解药物，大幅减少到达吸收界面的完整药物分子数量；其二，未被降解的完整药物分子抵达肠道上皮后，黏液层和上皮屏障会进一步限制药物的扩散和跨膜转运。围绕上述 2 类限制性因素，目前的应对思路有 3 种，包括在分子层面进行结构修饰、在制剂层面引入功能性辅料、优化给药递送方式，分别作用于药物本身、胃肠道局部微环境及药物进入体循环的途径。 3.1.1 优化结构提升蛋白及多肽类药物口服吸收 分子结构修饰通过改造药物自身理化性质，提高蛋白及多肽类药物对胃肠道环境的耐受性和跨膜转运能力，增加抵达吸收界面的完整药物分子数量。常见改造方式包括氨基酸位点替换、外源功能基团修饰和多肽骨架环化，可根据药物在口服递送过程中的主要限制机制选择合适的改造方式。对于酶切位点或降解敏感位点明确的药物，替换关键氨基酸残基是最直接的优化方式。采用非天然氨基酸替换天然氨基酸残基可有效降低药物在体内的酶解损耗，将GLP-1 第 8 位丙氨酸替换为 α-氨基异丁酸后，药物体外半衰期可由 0.3 h 延长至 5 h[24]。若药物的酶切位点尚不明确，则可从分子整体表面特性入手优化。PEG 化、脂肪酸化等外源基团修饰能够在药物分子表面形成空间位阻或水化保护层，减少蛋白酶与药物底物的接触概率，抑制药物降解。例如，生长抑素类似物经 PEG 修饰后，体内半衰期由 15 min 延长至 240 min 以上[14]。多肽环化修饰更适用于线性结构或构象柔性较强的蛋白及多肽类药物，通过分子头尾或侧链连接限制构象自由度、减少游离末端暴露，并重构分子表面疏水区域。环化后的药物既能抵御外肽酶水解，还能增强与细胞膜的相互作用，提升跨膜转运能力。经硫醚环化修饰的抗血栓环肽在大鼠模型中的经口生物利用度可达约 18%[25]；经骨架优化的 Kirsten 大鼠肉瘤病毒癌基因同源物靶向环肽，受体亲和力提升约 10 倍，跨上皮渗透能力达到有效给药阈值[26]。总体而言，结构修饰并非对药物分子进行普遍性改造，而是针对药物主要受限因素进行定向优化，更适用于功能位点明确、构效关系清晰且骨架结构具备改造空间的蛋白及多肽类药物。需注意的是，结构修饰在提高药物稳定性的同时，也可能影响受体结合区域或关键构象，进而降低生物活性，影响整体给药效果。 3.1.2 应用辅料改善胃肠道局部吸收环境 引入功能性辅料可改善蛋白及多肽类药物在胃肠道中的结构稳定性和跨屏障转运条件，按作用机制可分为局部环境调节型、屏障可逆调节型及复合功能型 3类。常见的缓冲体系和酶抑制剂属于局部环境调节型辅料，通过调控胃肠道 pH 或抑制蛋白酶活性，减少药物在到达吸收界面前的降解消耗。例如，鲑降钙素制剂中加入柠檬酸盐后可有效抑制胃蛋白酶活性，犬模型中药物全身暴露量提高 2 ~ 4 倍[27]；胰岛素与大豆胰蛋白酶抑制剂联用后，大鼠小肠中的药物降解率降低约 60%[28]。屏障可逆调节型辅料通过改变细胞膜流动性或可逆打开肠道紧密连接提高药物的跨上皮转运效率。该类辅料种类很多，作用强度与安全性差异较为明显。其中，脱氧胆酸钠和十二烷基硫酸钠等离子型表面活性剂对细胞膜结构扰动作用较强，促渗效率高但安全剂量窗口较窄；月桂基聚乙二醇甘油酯、泊洛沙姆等非离子型辅料作用则相对温和，主要通过改善药物分散状态、调控膜脂微环境促进药物转运[29]。因此，制剂处方设计需兼顾促渗效率和黏膜安全性。复合功能型辅料兼具环境调节和屏障调控双重作用，其应用效果取决于药物、辅料与给药部位微环境的适配性。以N‑[8‑（2‑羟基苯甲酰）氨基]辛酸钠[sodium N‑[8‑(2‑hydroxybenzoyl) amino] caprylate， SNAC] 为 例 ，该辅料可调节胃内局部 pH 并改善细胞膜流动性，可将司美格鲁肽口服生物利用度由几乎不可检测提升至 0.8% ~ 1.2%[30]；与癸酸钠联用后还能使 GLP-1类似物及前蛋白转化酶枯草溶菌素 9 （proprotein convertase subtilisin/kexin type 9，PCSK9） 抑制剂在细胞水平的促渗效率提升 10 ~ 40 倍[31]。离子液体体系也属于复合功能型促渗辅料，如胆碱-水杨酸盐能将胰岛素在犬模型中的经口生物利用度提升至6.5%[32]；癸酸胆碱离子凝胶可使大鼠体内胰岛素血药浓度较传统离子液体提高约 7 倍[33]。需注意的是，功能性辅料的促渗效果存在分子尺寸依赖性，中小型短肽和小分子蛋白通常能获得较为明显的改善，抗体类大分子则较难突破上皮屏障实现高效跨膜转运。 3.1.3 改变递送方式克服吸收屏障 对于分子量较大、跨上皮转运能力较弱，或难以依靠常规促渗辅料获得稳定吸收的蛋白及多肽类药物，可考虑通过改变递送方式缩短药物体内转运途径，促进药物直接入血。机械递送装置是近年研究较多的新型递送手段，通过微针穿刺、射流穿透或黏膜黏附固定等物理方式，将药物直接递送至黏膜下层或靶组织内部。基于仿刺鲀结构设计的水凝胶膨胀微针机器人，可显著提高胰岛素在猪体内的经口吸收效率，使其相对生物利用度达到 23.6%[34]；基于仿乌贼喷射机制构建的 MiDe 系统，可通过外部触发形成高速微射流实现黏膜快速穿透，在降低组织损伤的同时，使胰岛素及 GLP-1 类似物在猪和犬模型中的降糖效果接近皮下注射给药水平[35]；DOAMS 体系通过肠壁穿刺与结构形变实现肠道机械互锁，延长药物局部滞留时间，可使司美格鲁肽在猪体内的最大血药浓度 （Cmax） 达到普通片剂的约 6 倍[36]。口腔递送则利用颊黏膜或舌下黏膜血供丰富、屏障较薄的特点，有效规避胃肠降解损耗，为蛋白及多肽类药物提供高效的非胃肠吸收入血途径。仿章鱼吸盘结构的颊部贴片可通过稳定黏膜黏附和局部机械拉伸增强黏膜通透性，使去氨加压素在犬模型中的生物利用度达到 16.4%[37]；颊部微针阵列可快速穿透黏膜并释放药物，将胰岛素在猪模型中的生物利用度提高到10%[38]；基于穿膜肽构建的舌下递送体系则可将单抗药物在小鼠体内的生物利用度提升至 50% 以上[39]。 上述递送策略可在一定程度上突破分子尺寸和上皮通透性对药物吸收的限制，但其临床转化仍受装置可控性、组织损伤风险、患者依从性及长期重复给药安全性等因素制约。 3.2 针对吸收后受限环节的递送策略 上述策略主要作用于胃肠道吸收受限环节，让更多药物进入体循环；但进入体循环后的药物还会受到组织分布、血浆蛋白结合、网状内皮系统摄取及肝肾清除等过程影响，导致有效暴露不足。因此，口服蛋白及多肽类药物递送策略不能只关注是否能吸收，还需综合考虑吸收后的体内处置过程。在此背景下，递送载体的理性设计逐渐受到关注，其主要思路是通过赋予药物靶向识别、环境响应和抗清除等功能，提升药物在作用部位的有效分布，减少药物进入体循环后的非特异性损耗。 3.2.1 调控体内分布促进靶部位富集 载体进入血液循环后会依次经历血液运输、器官富集、组织渗透和细胞摄取等过程，各环节共同决定药物最终在靶部位的有效暴露水平。对于口服蛋白及多肽类药物，吸收后的制剂设计不再局限于提高血浆中的总药物暴露量，而是侧重提升药物对靶器官、靶组织或靶细胞的精准递送能力，降低非靶部位的无效分布。这一目标可通过载体表面修饰靶向配体增强组织、细胞识别能力，或利用靶组织微环境触发药物释放实现。以胰岛素经口递送为例，具有可切换表面配体的仿病毒载体可在循环过程中暴露半乳糖基团，经由去唾液酸糖蛋白受体介导被肝细胞识别，使胰岛素在小鼠肝组织中的富集比例达到 71.9%[40]。载体到达靶组织后，还可利用其局部微环境特征进一步调控药物释放行为。例如，肝脏内较强的还原性微环境可触发二硫键断裂，实现胰岛素的肝脏响应释放，该递送体系可使胰岛素在猪体内的经口生物利用度达到 20.4%[13]；将苯硼酸基团引入载体结构则能够赋予体系葡萄糖响应特性，使胰岛素释药行为与机体血糖水平变化相匹配，降低低血糖不良反应的发生风险[41]。因此，分布调控的目的不仅在于提高药物在局部组织的累积量，更在于保障药物在起效部位形成充足且持续的有效暴露，配体靶向识别与环境响应释药的协同设计能够有效实现药物靶向富集与可控释放的双重需求。 3.2.2 规避非特异性清除延长有效滞留 蛋白及多肽类药物载体进入体循环后的有效暴露时长还会受到血浆蛋白非特异性吸附、网状内皮系统摄取和胞内溶酶体降解等过程的影响。血液循环中的药物清除多与蛋白冠形成和免疫细胞非特异性识别相关，因此通过调控载体表面电荷和亲水性可有效抑制上述非特异性相互作用。两性离子聚合物可在载体表面形成电中性、高水化界面，减少血浆蛋白吸附和免疫细胞吞噬，延长载体体内循环滞留时间[42]。此外 ，引入新生儿Fc受体（neonatal Fc receptor，FcRn）结合肽可利用 FcRn 介导的循环回收通路，使部分被库普弗细胞摄取的载体重新释放至血液循环，减少肝脏网状内皮系统清除，延长艾塞那肽等药物的体内循环时长[43]。除循环阶段的清除损耗外，载体被细胞摄取后还可能被溶酶体降解，进一步造成药物损失。载体的形貌和力学性质可显著影响胞内转运与降解过程：棒状结构可延缓内体向溶酶体转变，并促进其向内质网相关路径转运，使棒状载体的细胞内递送效率较球形载体提高约 3 倍[44]；刚度适中的载体更易通过膜融合方式进入细胞质，膜融合效率可达 57.8%，能够有效减少药物的溶酶体降解损耗[45]。同时，引入 pH 响应电荷转换等内体逃逸结构也可进一步提升药物的胞质释放效率[46]。总的来说，抗蛋白吸附、减少免疫清除和促进内体逃逸等策略能够分别降低循环阶段和细胞内处置阶段的药物损耗。实际制剂设计中，可结合蛋白及多肽类药物的分子特性及主要受限环节，灵活联用多种优化策略，最大化提升药物体内有效暴露水平。 3.3 不同递送策略的适用范围与临床转化瓶颈 吸收阶段的递送策略可有效改善蛋白及多肽类药物的体内全身暴露水平，但其作用效果与药物分子自身性质密切相关。短肽分子结构简单、构效关系明确，结构修饰和促渗体系对该类分子通常具有较好的适用性；分子量一旦增大、构象趋于复杂，上述递送方法的作用效果会显著下降。结构修饰的潜在缺陷在于可能扰乱药物活性构象、破坏受体结合位点，进而诱发新的免疫原性风险。促渗辅料对上皮组织通透性的提升作用有限，无法实现抗体类大分子药物的有效递送，且其促渗效果易受处方组成和给药条件的影响。例如，SNAC 对胰岛素口服吸收的增强作用显著依赖于药物与辅料浓度配比、局部酸碱环境等条件[47]，该类条件依赖性会导致药物体内吸收行为产生明显波动。机械递送装置和口腔递送途径对药物自身跨膜能力要求较低，可适用于大分子量抗体药物的递送，但该类技术的临床应用仍受给药场景、操作复杂程度、制备成本和患者耐受度等因素的制约（见表 1）。 相较于传统吸收阶段递送方式，递送载体的理性设计策略可同步调控吸收受限环节和吸收后的分布及清除等体内处置过程，对不同类型蛋白及多肽类药物均表现出更广的使用范围。但随着载体功能化程度提高，载体结构和制备工艺也变得更加复杂。载体制备过程中，需协同调节形貌、粒径、力学性质、表面电荷和配体修饰密度等参数，且不同参数之间相互影响，导致载体制备质量易受反应环境、原料批次和规模化生产工艺的影响，批次间一致性问题也成为制约其工艺转化的难点。载体进入生物体内后，在体循环、组织滞留和生物降解过程中还可能引发补体激活、巨噬细胞摄取或免疫原性反应等不良反应，存在潜在安全隐患。此外，目前相关研究仍多集中于递送体系的短期评价，重复给药条件下的全身安全性数据仍相对缺乏（见表 1）。对于糖尿病、肥胖、骨质疏松等需长期持续给药的慢性疾病，该研究短板的影响更为突出。因此，口服蛋白及多肽类药物递送体系的综合评价不应只关注短期生物利用度，还应结合全身暴露稳定性、PK/PD相关性、重复给药安全性、规模化生产可行性和患者用药依从性等因素，综合判定其临床转化潜力与应用价值。 4 临床研究与转化进展 目前已获批的口服蛋白及多肽类药物可大致分为 2 类（见表 2）。一类药物主要在胃肠腔道或局部黏膜起效，全身吸收程度较低，代表药物为利那洛肽和普卡那肽，作用靶点为肠腔侧鸟苷酸环化酶 C受体。对于该类药物，较低的全身吸收能够有效规避非必要的全身暴露及相关不良反应，因此其制剂设计开发重点在于提升药物在胃肠道中的结构稳定性并维持局部有效浓度[48]。另一类药物占大多数，需突破胃肠道生理屏障进入体循环后发挥全身治疗作用。此类药物的口服成药潜力主要取决于分子特性与吸收调控策略的匹配程度，即在跨屏障吸收受限的前提下，能否获得满足疗效需求且相对稳定的全身暴露水平。围绕这一目标，目前已形成多种较为明确的技术路径，与前文所述的各类递送策略相对应。去氨加压素和伊可白滞素等环肽药物是通过结构优化实现口服应用的典型案例。环化修饰结构可显著提升药物的胃肠道稳定性，在减少酶促降解的同时维持药理活性[49-50]。针对司美格鲁肽、奥曲肽等中小分子量短肽药物，联合 SNAC、辛酸钠等促渗剂后，可在一定程度上改善其吸收受限的问题。该类药物的绝对生物利用度仍处于较低水平，但当药物分子特征、递送技术与体内暴露模式相互匹配时，仍可形成满足疗效需求的全身暴露量[14]。环孢素 A 具有较强的亲脂性，适合采用自乳化药物递送体系，有效改善了药物水溶性与跨膜吸收效率，其口服生物利用度可达约 30%[24]。但该技术路径具有明显的分子特异性，难以直接应用于多数亲水性较强、跨膜能力较弱的药物。因此，口服蛋白及多肽类药物的临床转化潜力，并不只是取决于绝对生物利用度的高低，还在于给药后能否形成稳定、可重复且满足临床疗效需求的全身暴露特征。 在研口服蛋白及多肽类药物管线大多仍将吸收过程作为优化重点，并根据各类药物分子理化特性调整处方组成与给药方案（见表 3）。新一代环肽候选分子常通过从头设计和骨架优化来提升构象稳定性与跨膜渗透能力，MK-0616 便是典型代表。该药物整合序列优化、大环化修饰与癸酸钠促渗技术，在临床研究中显示出接近单抗注射制剂的降脂治疗效果[51]。对于受体结合依赖天然构象的多肽药物，制剂优化多聚焦于调控药物体内释放行为。口服甲状旁腺激素 （1-34） 制剂 EB613 采用 N-TabTM 口服多肽递送平台，可在小肠部位实现快速释药与高效吸收，形成短时峰值暴露特征，临床研究证实其可在 6 个 月 内 将 受 试 者 腰 椎 骨 密 度 增 加 2.7% ~3.1%[52]。大分子量抗体类蛋白较难通过传统跨上皮渗透路径实现口服给药，主要依靠机械递送装置突破生理限制，RaniPillTM等递送系统可使口服单抗类药物达到与皮下注射制剂相近的全身暴露水平[53]。 部分开发受阻的案例证实，单纯提高吸收效率并不足以稳定保障长期给药后的全身暴露和临床疗效。诺华制药研发的口服降钙素 SMC021 就是一例，该药在Ⅲ期临床试验中未达到主要终点，长期全身暴露不稳定、个体间药效差异显著、量效关系不明确及促渗体系作用不足，都可能是导致试验失败的潜在因素[1]。另有口服多肽药物研究发现，药物全身暴露水平易受机体进食状态影响，暴露量的大幅波动会导致长期临床疗效难以精准预判[55]。Biocon 公司开发的口服胰岛素制剂 IN-105 采用结构修饰策略，有效改善了药物分子稳定性和早期胃肠道吸收效率，但结构修饰可能干扰了胰岛素与受体的结合，使入血后药效转化效果未达临床预期[56]。采用 SNAC 递送体系的口服 PCSK9 抑制剂 NNC0385-0434 在Ⅱ期临床试验中降脂效果明显，但需每日持续给药才能维持有效全身暴露量，大幅增加了长期治疗的用药负担，降低患者用药依从性[57]。上述案例从不同角度说明，吸收效率改善仅为口服蛋白及多肽类药物临床转化的基础条件，而非最终标准。药物进入体循环后能否保持完整生物活性、在实际给药条件下持续产生稳定药效，才是决定其能否成药的关键。 对比分析成功上市与开发受阻的药物案例可知，口服蛋白及多肽类药物的临床转化效果并不取决于单一的吸收效率提升。吸收增强仅能增加药物进入体循环的概率，稳定的临床疗效还依赖于药物在有效治疗窗口期内维持持续全身暴露，且该暴露特征需与药物半衰期、药效强度、受体作用时长和临床给药需求相匹配。对于半衰期较长、药效较强或受体结合作用较持久的药物分子，即便口服吸收程度有限，但相对稳定的低水平吸收也可通过后续药效放大效应，转化为可观的临床获益。反之，对于半衰期短、体内清除速率快或治疗窗口较窄的药物，即便通过技术手段提升了吸收效率，若难以维持进入体循环后的暴露量，仍可能出现疗效波动、给药频次过高或长期用药依从性不足等问题。因此，蛋白及多肽类药物的口服递送策略能否带来实际的临床获益，不仅受到药物吸收量本身的影响，还取决于该策略能否与药物体内分布和清除过程相匹配。这一规律也解释了同类递送体系转化结果不同的原因。部分体系能够顺利进入临床应用，而部分体系仍停留在基础研究阶段。对于转化效果优异的递送体系，当药物的主要限制环节集中于吸收阶段，且其半衰期、药效强度或受体作用时长可缓冲低吸收量带来的暴露波动时，围绕局部释药、促渗吸收或结构稳定性的优化手段更易实现稳定的疗效。相比之下，开发受阻的递送体系通常仅提高早期吸收效率，未解决吸收后的暴露维持、体内清除等问题，无法支撑长期临床治疗需求。 基于上述案例规律，能够提炼出可迁移的药物开发思路：在口服蛋白及多肽类药物早期研发阶段，需将“吸收—分布—清除”的完整体内过程作为整体评价体系，而非单一认定吸收过程为成药的唯一瓶颈。对于易降解或跨膜能力不足，但半衰期较长、药效强或作用持久的药物分子，可优先通过结构稳定修饰、局部靶向释药或促渗吸收等手段优化吸收过程；对于半衰期短、清除快或需长期平稳暴露的药物分子，则需在吸收优化的基础上，同步整合缓释、组织滞留、清除规避或给药方案优化等技术手段。此外，各类递送技术均存在明确的药物适用范围，表现出明显的分子特异性。SNAC 递送体系的成功依赖于司美格鲁肽自身较好的稳定性、较长半衰期和较强药效活性，不能直接套用至易降解、短效、清除较快的药物；环化修饰和骨架约束技术更适用于构效关系明确、可耐受结构改造的短肽或环肽药物；机械递送装置虽可规避上皮屏障的吸收限制，但受限于制备成本、操作复杂度和患者接受度，更适用于高价值、低频给药且传统促渗体系难以发挥作用的大分子药物。因此，口服蛋白及多肽类药物的临床转化评价体系需从单一评价转向综合评价，重点明确药物主要限制环节、适应证所需的体内暴露模式，以及递送策略能否同时满足吸收改善和后续暴露维持的要求，以此提升全身暴露水平的稳定性和可预测性。同时，研发与评价过程还需充分考虑进食状态、胃肠排空节律、疾病状态和重复长期给药等临床变量，最大限度降低不同应用场景下的个体内和个体间药效差异。 5 总结与展望 蛋白及多肽类药物口服递送策略的筛选与优化需基于药物自身分子属性开展。口服递送体系开发的思路是通过明确药物全身暴露不足的主要原因及关键的受限环节，选择与其分子特征和药效需求相匹配的递送技术。围绕这一思路，未来的相关研究可综合考虑以下 3 个方面。其一，明确不同分子特征对应的主要受限环节。不同结构与理化性质的药物在口服给药后面临的问题存在显著差异。构象稳定性差、易受胃酸及蛋白酶降解的药物分子，提高其在胃肠道中的结构稳定性通常是保障后续吸收入血的前提；亲水性强、跨膜能力弱、易被消化道黏液吸附滞留的药物分子，其成药瓶颈主要集中在黏液扩散和上皮跨膜转运过程；而对于可部分进入体循环的药物分子，组织分布效率和体内清除速率会进一步调控其全身暴露水平。明确药物分子特征与体内受限环节的对应关系，是精准设计递送策略的前提条件。其二，针对主要受限环节进行靶向递送优化。递送体系的功能复杂程度并不直接决定递送效果，递送技术能否突破药物主要成药瓶颈是提升给药效果的决定性因素。针对入血前存在明显障碍的药物，研究重点需聚焦于提升胃肠道结构稳定性、维持吸收部位有效药物浓度、提高跨屏障转运效率；针对入血后体内过程受限的药物，则需进一步调控组织分布行为、延长靶部位滞留时间、减少非特异性清除。相应地，药效评价指标也应从单一的生物利用度，转向稳定、可重复且与临床药效相关的全身暴露水平。其三，推动递送策略由单一环节优化向过程协同优化升级。结构修饰、促渗辅料应用、局部微环境调控、机械递送与载体设计等技术手段，可根据药物分子特征组合联用，但技术联用应遵循明确的适配原则。结构明确、主要受限于吸收阶段的短肽药物，可优先采用相对简易的促吸收策略；构象复杂、分子量较大或吸收后暴露维持能力不足的药物，则需在改善吸收的同时引入分布调控和清除规避的一体化设计。在此过程中，还需兼顾制备工艺可控性、批次质量一致性、长期用药安全性和临床应用便利性，推动口服蛋白及多肽类药物递送研究从传统经验性策略筛选过渡到基于分子属性和体内过程规律的系统设计。 参考文献： [1] Xiao W, Jiang W, Chen Z, et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines[J].Signal Transduct Target Ther, 2025, 10(1): 74. [2] Hornsby B D, Lee C H, Steele C A, et al. Therapeutic peptides and proteins: status and developments in drug delivery[J]. J Control Release, 2026, 394: 114895. [3] 药渡经纬信息科技(北京)有限公司. 药渡全球药物研发数据库[DB/OL]. (2026-04-24）[2026-04-30]. https://www.drugsnav.com/. [4] Steiger M B, Steinauer A, Gao D, et al. Enzymatic absorption promoters for non-invasive peptide delivery[J]. J Control Release, 2025, 382: 113675. [5] Brayden D J, Hill T A, Fairlie D P, et al. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches[J]. Adv Drug Deliv Rev, 2020, 157:2-36. [6] Spleis H, Sandmeier M, Claus V, et al. Surface design of nanocarriers: key to more efficient oral drug delivery systems[J]. Adv Colloid Interface Sci, 2023, 313: 102848. [7] Zhang X, Peng C, Zhang W, et al. Glucose-responsive polyzwitterionic nanoparticles with enhanced and targeted intestinal epithelial absorption for oral insulin delivery[J]. ACS Nano, 2025, 19(29): 26871-26881. [8] Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1receptor: mechanisms and advances in therapy[J]. Signal Transduct Target Ther, 2024, 9(1): 234. [9] Hu H, Quintana J, Weissleder R, et al. Deciphering albumindirected drug delivery by imaging[J]. Adv Drug Deliv Rev,2022, 185: 114237. [10] Glatard A, Friberg-Hietala S, Keutzer L, et al. Population pharmacokinetic analysis of an octreotide depot (CAM2029) in the treatment of acromegaly[J]. Clin Pharmacokinet, 2025, 64(7): 1079-1092. [11] 杨甜甜, 王奥华, 俞淼荣, 等. 蛋白多肽类降糖药物口服递送载体的研究现状与临床应用进展[J]. 药学进展, 2022, 46(4):255-269. [12] Martínez-López A L, González-Navarro C J, Aranaz P, et al. In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions[J]. Acta Pharm Sin B, 2021, 11(4):989-1002. [13] Xia B, Xu F, Chen J, et al. Site-specific adaptive nanovesicles for oral insulin delivery[J]. Sci Adv, 2025, 11(39): eady6386. [14] Niazi S K. Oral delivery of peptides and proteins:pharmacokinetic boundaries, negative selection, and route triage[J]. Front Drug Deliv, 2026, 6: 1776167. [15] La Salvia A, Modica R, Rossi R E, et al. Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists[J]. Cancer Treat Rev, 2023, 117: 102560. [16] Kotynia A, Marciniak A, Kamysz W, et al. Interaction of positively charged oligopeptides with blood plasma proteins[J]. Int J Mol Sci, 2023, 24(3): 2836. [17] Peri R V, Anchan H, Jonnalagadda K, et al. Designing GLP-1delivery: structural perspectives and formulation approaches for optimized therapy[J]. Nutr Diabetes, 2025, 15(1): 53. [18] Wang Q, Chen Z, Zhang G, et al. Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors[J]. Science, 2026, 391(6791): eadu7686. [19] Tsoi K M, MacParland S A, Ma X Z, et al. Mechanism of hardnanomaterial clearance by the liver[J]. Nat Mater, 2016, 15(11): 1212-1221. [20] Polesel M, Kaminska M, Haenni D, et al. Spatiotemporal organisation of protein processing in the kidney[J]. Nat Commun, 2022, 13: 5732. [21] Sitovs A, Mohylyuk V. Ex vivo permeability study of poorly soluble drugs across gastrointestinal membranes: acceptor compartment media composition[J]. Drug Discov Today, 2024,29(12): 104214. [22] Siddiqui S, Ameen F, ur Rehman S, et al. Studying the interaction of drug/ligand with serum albumin[J]. J Mol Liq,2021, 336: 116200. [23] Musther H, Olivares-Morales A, Hatley O J D, et al. Animal versus human oral drug bioavailability: do they correlate? [J].Eur J Pharm Sci, 2014, 57: 280-291. [24] Ding B, Zhu Z, Guo C, et al. Oral peptide therapeutics for diabetes treatment: state-of-the-art and future perspectives[J].Acta Pharm Sin B, 2024, 14(5): 2006-2025. [25] Merz M L, Habeshian S, Li B, et al. De novo development of small cyclic peptides that are orally bioavailable[J]. Nat Chem Biol, 2024, 20(5): 624-633. [26] Tanada M, Tamiya M, Matsuo A, et al. Development of orally bioavailable peptides targeting an intracellular protein: from a hit to a clinical KRAS inhibitor[J]. J Am Chem Soc, 2023, 145(30): 16610-16620. [27] Bohley M, Leroux J C. Gastrointestinal permeation enhancers beyond sodium caprate and SNAC - what is coming next?[J].Adv Sci (Weinh), 2024, 11(33): e2400843. [28] Ghavami M, Pedersen J, Kjeldsen R B, et al. A self-unfolding proximity enabling device for oral delivery of macromolecules[J]. J Control Release, 2023, 361: 40-52. [29] Ejazi S A, Louisthelmy R, Maisel K. Mechanisms of nanoparticle transport across intestinal tissue: an oral delivery perspective[J]. ACS Nano, 2023, 17(14): 13044-13061. [30] Buckley S T, Bækdal T A, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1receptor agonist[J]. Sci Transl Med, 2018, 10(467): eaar7047. [31] Niu Z, La Zara D, Blaabjerg L, et al. Combining SNAC and C10 in oral tablet formulations for gastric peptide delivery: a preclinical and clinical study[J]. J Control Release, 2025, 378:92-102. [32] Rebollo R, Niu Z, Blaabjerg L, et al. Salcaprozate-based ionic liquids for GLP-1 gastric delivery: a mechanistic understanding of in vivo performance[J]. J Control Release,2025, 377: 267-276. [33] Raptis K, Heade J, Cunha C, et al. Permeation enhancer-based ionogel shows remarkable potential for oral insulin delivery[J].Adv Healthc Mater, 2025, 14(20): e2500946. [34] Gao X, Li J, Li J, et al. Pain-free oral delivery of biologic drugs using intestinal peristalsis–actuated microneedle robots[J]. Sci Adv, 2024, 10(1): eadj7067. [35] Arrick G, Sticker D, Ghazal A, et al. Cephalopod-inspired jetting devices for gastrointestinal drug delivery[J]. Nature,2024, 636(8042): 481-487. [36] Chen W, Wainer J, Ryoo S W, et al. Dynamic omnidirectional adhesive microneedle system for oral macromolecular drug delivery[J]. Sci Adv, 2022, 8(1): eabk1792. [37] Luo Z, Klein Cerrejon D, Römer S, et al. Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch[J]. Sci Transl Med, 2023, 15(715): eabq1887. [38] Caffarel-Salvador E, Kim S, Soares V, et al. A microneedle platform for buccal macromolecule delivery[J]. Sci Adv, 2021,7(4): eabe2620. [39] Kelly S H, Wu Y, Varadhan A K, et al. Enabling sublingual peptide immunization with molecular self-assemblies[J].Biomaterials, 2020, 241: 119903. [40] Yang T, Wang A, Nie D, et al. Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy[J]. Nat Commun, 2022, 13(1):6649. [41] Ji K, Wei X, Kahkoska A R, et al. An orally administered glucose-responsive polymeric complex for high-efficiency and safe delivery of insulin in mice and pigs[J]. Nat Nanotechnol,2024, 19(12): 1880-1891. [42] Fang H, Chen L, Deng Z, et al. In situ polymerization of zwitterions on therapeutic proteins to enable their effective oral delivery[J]. ACS Nano, 2023, 17(2): 1128-1143. [43] Wang J, Zhang Z, Zhang Z, et al. Enhanced gut-to-liver oral drug delivery via ligand-modified nanoparticles by attenuating protein corona adsorption[J]. ACS Nano, 2024, 18(52): 35310-35324. [44] Liang L, Wang N, Li X, et al. Shape engineering of exosomes for endoplasmic reticulum-targeted delivery and amplified anticancer efficacy[J]. Nano Today, 2024, 57: 102377. [45] Zhuo Y, Luo Z, Zhu Z, et al. Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes[J]. Nat Nanotechnol, 2024, 19(12): 1858-1868. [46] Xi Z, Ahmad E, Zhang W, et al. Dual-modified nanoparticles overcome sequential absorption barriers for oral insulin delivery[J]. J Control Release, 2022, 342: 1-13. [47] Jørgensen J R, Jepsen M L, Nielsen L H, et al. Microcontainers for oral insulin delivery – In vitro studies of permeation enhancement[J]. Eur J Pharm Biopharm, 2019, 143: 98-105. [48] Hindson J. Linaclotide for functional constipation in paediatric patients: phase III results[J]. Nat Rev Gastroenterol Hepatol,2024, 21(3): 141. [49] Glavaš M, Gitlin-Domagalska A, Dębowski D, et al.Vasopressin and its analogues: from natural hormones to multitasking peptides[J]. Int J Mol Sci, 2022, 23(6): 3068. [50] Bissonnette R, Soung J, Hebert A A, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents[J]. N Engl J Med,2025, 393(18): 1784-1795. [51] Navar A M, Mikhailova E, Catapano A L, et al. A placebocontrolled trial of the oral PCSK9 inhibitor enlicitide[J]. N Engl J Med, 2026, 394(6): 529-539. [52] Tripto-Shkolnik L, Szalat A, Tsvetov G, et al. Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study[J]. J Bone Miner Res, 2024, 39(6):672-682. [53] Abramson A, Caffarel-Salvador E, Khang M, et al. An ingestible self-orienting system for oral delivery of macromolecules[J]. Science, 2019, 363(6427): 611-615. [54] Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability,pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-inhuman, phase 1, double-blind, randomised, placebo-controlled trial[J]. Lancet, 2025, 406(10499): 135-148. [55] Maher S, Brayden D J. Formulation strategies to improve the efficacy of intestinal permeation enhancers[J]. Adv Drug Deliv Rev, 2021, 177: 113925. [56] Drucker D J. Advances in oral peptide therapeutics[J]. Nat Rev Drug Discov, 2020, 19(4): 277-289. [57] Bao X, Liang Y, Chang H, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside[J]. Signal Transduct Target Ther, 2024, 9(1): 13.  本文引文格式： 贾蓓,高铎,吴佳淇,等.蛋白及多肽类药物口服递送策略的研究现状及思考[J].药学进展,2026,50(4):334-345. 美编排版：方正 感谢您阅读《药学进展》微信平台原创好文，也欢迎各位读者转载、引用。本文选自《药学进展》2026年第 4 期。 《药学进展》杂志由教育部主管、中国药科大学主办，中国科技核心期刊（中国科技论文统计源期刊）。刊物以反映药学科研领域的新方法、新成果、新进展、新趋势为宗旨，以综述、评述、行业发展报告为特色，以药学学科进展、技术进展、新药研发各环节技术信息为重点，是一本专注于医药科技前沿与产业动态的专业媒体。 《药学进展》注重内容策划、加强组稿约稿、深度挖掘、分析药学信息资源、在药学学科进展、科研思路方法、靶点机制探讨、新药研发报告、临床用药分析、国际医药前沿等方面初具特色；特别是医药信息内容以科学前沿与国家战略需求相合，更加突出前瞻性、权威性、时效性、新颖性、系统性、实战性。根据最新统计数据，刊物篇均下载率连续三年蝉联我国医药期刊榜首，复合影响因子1.311，具有较高的影响力。 《药学进展》编委会由国家重大专项化学药总师陈凯先院士担任主编，编委由新药研发技术链政府监管部门、高校科研院所、制药企业、临床医院、CRO、金融资本及知识产权相关机构近两百位极具影响力的专家组成。 联系《药学进展》↓↓↓ 编辑部官网：pps.cpu.edu.cn； 邮箱：yxjz@163.com； 电话：025-83271227。 欢迎投稿、订阅！ 往期推荐 聚焦“第七届药学前沿学术论坛暨《药学进展》编委会会议” 聚力前沿赛道，共启学术新程：第七届药学前沿学术论坛在南京隆重启幕 承学术匠心，启时代新章：《药学进展》第七届编委会、第三届青年编委会成立大会在宁召开 聚焦“兴药为民·2023生物医药创新融合发展大会”“兴药为民·2023生物医药创新融合发展大会”盛大启幕！院士专家齐聚杭城，绘就生物医药前沿赛道新蓝图“兴药强刊”青年学者论坛暨《药学进展》第二届青年编委会议成功召开“兴药为民·2023生物医药创新融合发展大会”路演专场圆满收官！校企合作新旅程已启航 我知道你在看哟

*本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放 截至07月30日15点59分，近期共有 616 本期刊发布了 1405 篇文章，其中糖尿病相关的文章共 311 篇，覆盖 36 个领域的内容。今日，影响因子最高的文章刊登在 The Lancet (IF: 88.500) 期刊上。 今日头条 Headlines 01 Lancet Diabetes Endocrinol IF: 41.800 GLP-1受体激动剂使用量激增 The Lancet Diabetes & Endocrinology 根据盖洛普最新分析，美国目前有11%的成年人正在使用注射用GLP-1或GIP/GLP-1受体激动剂（如司美格鲁肽、利拉鲁肽、替尔泊肽）进行减肥，这一比例在两年内增长了近四倍。分析还发现，曾使用过这些药物减肥的成年人比例从2024年的6%上升至2026年的15%。 这一增长与美国成人肥胖率的下降呈负相关——肥胖率从2022年的39.9%降至2026年的36.4%——表明GLP-1受体激动剂用于减肥的日益普及正在产生一定的人群层面效应。 现有药物的更广泛应用、更有效减肥药物的开发以及口服制剂的推广使用，可能进一步降低肥胖率。然而，只有消除当前和未来减肥药物的获取障碍（成本和资格），肥胖格局的转变才有可能实现。2026年的一项研究估计，全球四分之一的成年人符合接受GLP-1受体激动剂进行体重管理的条件，其中约80%生活在低收入和中等收入国家。然而，差异显著：高收入国家的合格率为42%，中等收入国家约为25%，低收入国家仅为12%；老年人（55-64岁）的合格率（38%）高于年轻人（25-34岁，18%）；女性（28%）略高于男性（25%）。 GLP-1受体激动剂使用增加与美国成人肥胖率下降的同步现象，表明这些药物有可能逆转全球数十年来肥胖率的持续上升。这些药物能否转化为惠及所有社会经济阶层的公共卫生成功，尚需时间检验。 本文由 天纳乾坤 编辑 扫描二维码查看源文 Lancet Diabetes Endocrinol | Ahead of Print. 10.1016/S2213-8587(26)00194-4 02 Cardiovascular Diabetology IF: 10.600 胰高血糖素样肽-1受体激动剂对心率的不同影响 Martin Lorenz, Francesca Lawson, David Owens, Denis Raccah, Christine Roy-Duval, Anne Lehmann, etc. 胰高血糖素样肽-1受体激动剂（GLP-1 RA）已知可增加心率，但不同药物间差异显著。本文综述了24小时平均心率监测数据，包括1112名健康受试者和2型糖尿病患者的活性治疗组数据，以及两项利司那肽与利拉鲁肽的头对头试验（202名患者）。 短效GLP-1 RA（艾塞那肽BID和利司那肽）导致瞬时心率增加，峰值在注射后2-4小时，约10-12小时后恢复基线，24小时平均增加1-3次/分。长效GLP-1 RA（利拉鲁肽、阿必鲁肽、度拉糖肽、艾塞那肽LAR）引起更显著且持续的心率增加，其中利拉鲁肽和阿必鲁肽增加6-10次/分，度拉糖肽和艾塞那肽LAR增加3-4次/分。利拉鲁肽和度拉糖肽的心率增加在白天和夜间均存在。 两项头对头试验显示，利司那肽导致心率小幅瞬时增加，而利拉鲁肽引起更大幅度的持续增加（24小时平均增加约9次/分 vs 3-4次/分）。心率增加的机制尚不完全清楚，可能与直接作用于窦房结GLP-1受体和/或交感神经系统激活有关，且与药物作用持续时间相关。 近期完成的LEADER和ELIXA试验表明，GLP-1 RA引起的心率增加，无论幅度大小，均不增加2型糖尿病患者的心血管风险。然而，在晚期心力衰竭患者中，明显的心率增加可能与不良临床结局相关。 本文由 天纳乾坤 编辑 扫描二维码查看源文 Cardiovascular Diabetology | Volume 16, Issue 1 10.1186/s12933-016-0490-6 03 Am J Psychiatry IF: 14.700 口服司美格鲁肽治疗酒精使用障碍：一项随机临床试验 Joseph P Schacht, Joseph T Sakai, Kristen Raymond, Robert Shelton, etc. 一项发表于《美国精神病学杂志》的2期随机双盲平行对照试验评估了口服司美格鲁肽对酒精使用障碍患者的疗效。研究纳入50名中重度酒精使用障碍患者，随机分配至司美格鲁肽组（前4周每日3 mg，后4周每日7 mg）或安慰剂组，治疗持续8周。主要终点为第6周实验室酒精线索诱发的渴求，关键次要重点为治疗最后4周的重度饮酒天数和每日饮酒量。 结果显示，司美格鲁肽未显著降低实验室评估的渴求或每日饮酒量，但显著减少了重度饮酒天数（b=-0.580，95% CI=-1.012~-0.148）。此外，司美格鲁肽还显著降低了每次饮酒量（b=-1.177，95% CI=-2.307~-0.047）、自然渴求（b=-2.195，95% CI=-4.174~-0.216）和大麻使用天数（b=-1.434，95% CI=-2.568~-0.301）。司美格鲁肽组酒精相关负面后果的改善速度显著快于安慰剂组（b=-4.618，95% CI=-8.651~-0.585），且更多司美格鲁肽组参与者将风险饮酒水平降低至少一级（Wald χ²=4.01）。 这些发现证实了先前在非治疗寻求且严重程度较轻的酒精使用障碍患者中的结果，提示继续开发司美格鲁肽用于酒精使用障碍是合理的。 本文由 韩玉莲 编辑 扫描二维码查看源文 Am J Psychiatry | Ahead of Print. 10.1176/appi.ajp.20260003 其他发布内容（308） More Published Articles British journal of anaesthesia IF: 09.200Ahead of Print.No.01Thiopental-associated diabetes insipidus in neurocritical care神经重症监护中硫喷妥钠相关性尿崩症DOI: 10.1016/j.bja.2026.06.022 European journal of pharmacology IF: 04.700Ahead of Print.No.02Combined Treatment with Metformin and Melatonin Improves Placental Mitochondrial Function via the AMPK/SIRT3 Pathway in an LPS-Induced Model of Preeclampsia二甲双胍与褪黑素联合治疗通过AMPK/SIRT3通路改善LPS诱导的子痫前期模型胎盘线粒体功能DOI: 10.1016/j.ejphar.2026.179196 Talanta IF: 06.100Ahead of Print.No.03Metformin-integrated luminescent hydrogen-bonded organic framework for rapid and selective fluorescent detection of hypochlorite二甲双胍整合的发光氢键有机框架用于次氯酸盐的快速选择性荧光检测DOI: 10.1016/j.talanta.2026.130359 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.04Type 1 Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation超越胰岛素的1型糖尿病管理：证据、研究与监管的协同DOI: 10.1016/j.ecl.2026.04.016 Phlebology IF: 01.500Ahead of Print.No.05Ultrasound criteria for upper extremity lipedema diagnosis上肢脂肪水肿诊断的超声标准DOI: 10.1177/02683555261475099 Neurological sciences IF: 02.400Volume 47, Issue 8No.06Reconsidering the non-obese phenotype of idiopathic intracranial hypertension重新审视特发性颅内高压的非肥胖表型DOI: 10.1007/s10072-026-09281-0 Gene therapy IF: 04.500Ahead of Print.No.07Bone- and muscle-targeted adeno-associated viral vectors enable tissue-selective vitamin D receptor knockdown in mice骨和肌肉靶向腺相关病毒载体实现小鼠组织选择性维生素D受体敲低DOI: 10.1038/s41434-026-00636-y International journal of obesity IF: 03.800Ahead of Print.No.08The increase in fat-free mass during weight loss does not prevent greater than predicted reductions in resting energy expenditure in recreational athletes减重期间去脂体重的增加不能阻止休闲运动员静息能量消耗的超预期下降DOI: 10.1038/s41366-026-02179-z International journal of obesity IF: 03.800Ahead of Print.No.09The short ACE2 isoform is upregulated in adipose tissue from women with obesity肥胖女性脂肪组织中短ACE2亚型表达上调DOI: 10.1038/s41366-026-02177-1 npj health systemsVolume 2, Issue 1No.10MuTATE: an interpretable multi-endpoint machine learning framework for automated molecular subtyping in cancerMuTATE：一种可解释的多终点机器学习框架用于癌症自动分子分型DOI: 10.1038/s44401-025-00025-4 Injury IF: 02.000Ahead of Print.No.11Progressive enhancement in cadaver-based trauma surgery simulation: A 22-course longitudinal evaluation of partecipant-reported realism, learning and satisfaction基于尸体的创伤手术模拟渐进式增强：22期课程纵向评估参与者报告的真实感、学习效果和满意度DOI: 10.1016/j.injury.2026.113513 Obes Res Clin Pract IF: 02.300Ahead of Print.No.12Maternal body mass index and risk of post-partum haemorrhage: A population-based study in primiparous women产妇体重指数与产后出血风险：一项基于初产妇的人群研究DOI: 10.1016/j.orcp.2026.07.002 Surg Obes Relat Dis IF: 03.800Ahead of Print.No.13Sedentary behaviors in the context of metabolic and bariatric surgery: a scoping review代谢与减重手术背景下的久坐行为：一项范围综述DOI: 10.1016/j.soard.2026.06.017 Zhonghua erke zazhiVolume 64, Issue 8No.14[Obesity characteristics and body composition in children with osteogenesis imperfecta]成骨不全症儿童的肥胖特征与身体成分DOI: 10.3760/cma.j.cn112140-20260205-00118 Ann Hepatobiliary Pancreat Surg IF: 01.700Ahead of Print.No.15New-onset diabetes after distal pancreatectomy-findings from a national cohort study远端胰腺切除术后新发糖尿病的全国队列研究结果DOI: 10.14701/ahbps.26-100 SoinsVolume 71, Issue 907No.16[Therapeutic patient education for obese adolescents: an opportunity to develop a personalized care plan]肥胖青少年的治疗性患者教育：制定个性化护理计划的机会DOI: 10.1016/j.soin.2026.06.005 BMJ open IF: 02.300Volume 16, Issue 7No.17Gestational weight gain and child nutritional outcomes in East Coast Peninsular Malaysia: protocol for the 10-year prospective GROW-MY cohort study马来西亚东海岸妊娠期体重增加与儿童营养结局：10年前瞻性GROW-MY队列研究方案DOI: 10.1136/bmjopen-2025-110200 Neuropharmacology IF: 04.600Ahead of Print.No.18Intracerebroventricular and intranasal application of alarin reduces body weight in male rats脑室内和鼻内应用alarin可降低雄性大鼠体重DOI: 10.1016/j.neuropharm.2026.111117 Am J Prev Med IF: 04.500Ahead of Print.No.19Clinical Obesity Beyond BMI Identifies a Large High-Risk Subgroup in UK Adults超越BMI的临床肥胖识别出英国成年人中一个大的高风险亚组DOI: 10.1016/j.amepre.2026.108527 South Dakota journal of medicineVolume 79, Issue 5No.20Increased Risk of Alcohol Use Disorder Following Bariatric Surgery减重手术后酒精使用障碍风险增加https://pubmed.ncbi.nlm.nih.gov/42525976 Diabetes IF: 07.500Ahead of Print.No.21Ciliary ARL13B Is Essential for Body Weight Regulation in Mice纤毛ARL13B对小鼠体重调节至关重要DOI: 10.2337/db25-1099 PloS one IF: 02.600Volume 21, Issue 7No.22Muscle activity and airflow dynamics upon gradual weight-gain volumetric enlargement or acute surgical reduction of the tongue base during chewing and swallowing舌根部渐进性增重体积增大或急性手术缩小对咀嚼和吞咽过程中肌肉活动及气流动力学的影响DOI: 10.1371/journal.pone.0352976 Dermatology IF: 02.700Ahead of Print.No.23Advances in current and emerging therapies for challenging cutaneous mucinoses with substantial morbidity and therapeutic complexity: A narrative review当前和新兴疗法在具有显著发病率和治疗复杂性的挑战性皮肤黏蛋白病中的进展：一项叙述性综述DOI: 10.1159/drm/ackag001 Obesity facts IF: 04.700Ahead of Print.No.24Diagnosing Obesity in Korean Children Using BMI and Body Fat Percentage: Differences in Growth and Body Composition使用体重指数和体脂率诊断韩国儿童肥胖：生长与身体成分的差异DOI: 10.1159/000553145 Epidemiology IF: 04.400Volume 37, Issue 5No.25Generalizing Findings in Nested Cohorts嵌套队列研究结果的泛化DOI: 10.1097/EDE.0000000000002012 Biochemical pharmacology IF: 05.600Ahead of Print.No.26Interleukin-38 attenuates Obesity-induced cardiomyopathy through AMPK/autophagy-mediated suppression of endoplasmic reticulum stress白细胞介素-38通过AMPK/自噬介导的内质网应激抑制减轻肥胖性心肌病DOI: 10.1016/j.bcp.2026.118301 SoinsVolume 71, Issue 907No.27[Care for a patient who has undergone a vascular amputation]血管截肢患者的护理DOI: 10.1016/j.soin.2026.06.012 Exp Clin Endocrinol Diabetes IF: 01.700Ahead of Print.No.28The Possible Role of Anti-Glutamic Acid Decarboxylase Antibody Levels in the Development of Celiac Disease in Children with Type 1 Diabetes抗谷氨酸脱羧酶抗体水平在1型糖尿病儿童乳糜泻发生中的可能作用DOI: 10.1055/a-2916-3044 Animal Bioscience IF: 02.500Ahead of Print.No.29Effects of heat stress on physiological, endocrine, and reproductive functions in swine: a review热应激对猪生理、内分泌和生殖功能的影响：综述DOI: 10.5713/ab.250866 Biochim Biophys Acta Mol Basis Dis IF: 04.200Ahead of Print.No.30EGR2 promotes vascular smooth muscle cell differentiation and proliferation in outward remodeling during arteriovenous fistula maturationEGR2通过促进血管平滑肌细胞分化和增殖在动静脉瘘成熟过程中的外向重塑中发挥作用DOI: 10.1016/j.bbadis.2026.168390 Cellular signalling IF: 03.700Ahead of Print.No.31The multifaceted role of cathepsin a in glioblastoma pathogenesis: from molecular scaffolding to immunological evasion组织蛋白酶A在胶质母细胞瘤发病机制中的多重作用：从分子支架到免疫逃逸DOI: 10.1016/j.cellsig.2026.112768 Experimental gerontology IF: 04.300Ahead of Print.No.32Interaction between mental and cardiometabolic health in relation to telomere length among university staff in Australia澳大利亚大学员工心理健康与心血管代谢健康对端粒长度的交互作用DOI: 10.1016/j.exger.2026.113255 Hormone and metabolic research IF: 01.800Ahead of Print.No.33Real-World Effectiveness and Safety of Recombinant Human Growth Hormone in Chinese Children with Noonan Syndrome: Long-Term Follow-up and a 2-Year Comparison of Short- and Long-Acting Formulations重组人生长激素在中国Noonan综合征儿童中的真实世界有效性和安全性：长期随访及短效与长效制剂的2年比较DOI: 10.1055/a-2900-8976 International immunopharmacology IF: 04.700Ahead of Print.No.34Dehydrodiisoeugenol ameliorates DSS-induced ulcerative colitis by suppression of cellular senescence through inhibiting AKT and activating GSK3B去氢二异丁香酚通过抑制AKT和激活GSK3B抑制细胞衰老改善DSS诱导的溃疡性结肠炎DOI: 10.1016/j.intimp.2026.117207 Ecotoxicol Environ Saf IF: 06.100Ahead of Print.No.35Paternal DEHP exposure causes male offspring glycometabolism disorders via sperm miR-10a-5p父代DEHP暴露通过精子miR-10a-5p导致雄性后代糖代谢紊乱DOI: 10.1016/j.ecoenv.2026.120594 Medicina IF: 02.400Volume 62, Issue 7No.36Reclassification of PAPSS2 Missense Variants in Turkish Patients with Brachyolmia Type 4: Multi-Modal Computational and Structural Biology Evidence for APS-Kinase Domain Dysfunction土耳其短躯干发育不良4型患者中PAPSS2错义变异的重新分类：APS激酶结构域功能失调的多模式计算与结构生物学证据DOI: 10.3390/medicina62071363 Nature genetics IF: 29.000Ahead of Print.No.37Translating genomic data into healthcare practice with the Singapore National Precision Medicine program新加坡国家精准医学计划将基因组数据转化为医疗实践DOI: 10.1038/s41588-026-02687-8 Heart & Lung IF: 02.600Ahead of Print.No.38Detection rate and risk factors of carotid atherosclerotic plaque in patients with obstructive sleep apnea syndrome: A systematic review and meta-analysis阻塞性睡眠呼吸暂停综合征患者颈动脉粥样硬化斑块的检出率及危险因素：系统评价与荟萃分析DOI: 10.1016/j.hrtlng.2026.102902 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.39Beyond Glycemia in T1D: Insulin Resistance and Multiorgan Injury in Type 1 Diabetes-Part 2超越血糖：1型糖尿病中的胰岛素抵抗与多器官损伤——第二部分DOI: 10.1016/j.ecl.2026.04.014 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.40Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1超越血糖：1型糖尿病中胰岛素抵抗与心肾风险的隐藏负担——第一部分DOI: 10.1016/j.ecl.2026.04.008 PloS one IF: 02.600Volume 21, Issue 7No.41Multimorbidity patterns and their associations with demographic characteristics, behavioral factors, and urban-rural residence: A latent class analysis in the Thai population泰国人口中多病共存模式及其与人口学特征、行为因素和城乡居住地的关联：一项潜在类别分析DOI: 10.1371/journal.pone.0354347 J Foot Ankle Surg IF: 01.300Ahead of Print.No.42Long-Acting Narcotic Multimodal Anesthesia Versus Standard of Care Anesthesia for Hallux Valgus Patients Undergoing a Percutaneous Distal Metatarsal Osteotomy: A Multi-Center Randomized Controlled Trial长效麻醉药多模式麻醉与标准护理麻醉对接受经皮远端跖骨截骨术的拇外翻患者的比较：一项多中心随机对照试验DOI: 10.1053/j.jfas.2026.07.023 Zhonghua erke zazhiVolume 64, Issue 8No.43[Guideline for diagnosis, treatment and prevention of type 1 diabetes mellitus in children(2026)]儿童1型糖尿病诊断、治疗与预防指南（2026）DOI: 10.3760/cma.j.cn112140-20260309-00194 Am J Physiol Endocrinol Metab IF: 03.100Ahead of Print.No.44PYY3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLDPYY3-36增强司美格鲁肽在代谢相关脂肪性肝病中的线粒体调节作用DOI: 10.1152/ajpendo.00036.2026 AJC IF: 02.100Ahead of Print.No.45GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Hypertrophic Cardiomyopathy with Type 2 Diabetes: A Propensity Score-Matched Real-World AnalysisGLP-1受体激动剂对比SGLT2抑制剂在肥厚型心肌病合并2型糖尿病中的疗效：一项倾向评分匹配的真实世界分析DOI: 10.1016/j.amjcard.2026.07.025 AJNR Am J Neuroradiol IF: 03.700Ahead of Print.No.46Glucagon-Like Peptide-1 Receptor Agonist Therapy and Neurocognitive Outcomes in Medically Managed Idiopathic Intracranial Hypertension: A Propensity Score-Matched Cohort Study胰高血糖素样肽-1受体激动剂治疗与药物管理的特发性颅内高压患者的神经认知结局：一项倾向评分匹配队列研究DOI: 10.3174/ajnr.A9559 Pediatric blood & cancer IF: 02.300Ahead of Print.No.47The Combined Effect of Obesity and Contraceptive Use on Pulmonary Embolism in Adolescent Females Residing in the United States肥胖与避孕药使用对美国青少年女性肺栓塞的联合影响DOI: 10.1002/1545-5017.70439 Trop Med Int Health IF: 02.300Ahead of Print.No.48Pathways to Care for Patients With Severe Chronic NCDs: A Cross-Sectional Survey of Inpatients in Neno Malawi严重慢性非传染性疾病患者的就医路径：马拉维Neno地区住院患者的横断面调查DOI: 10.1111/tmi.70211 Zhonghua erke zazhiVolume 64, Issue 8No.49[Construction of a risk prediction model for vascular function damage in children with primary hypertension]原发性高血压儿童血管功能损伤风险预测模型的构建DOI: 10.3760/cma.j.cn112140-20251119-01039 Biomolecules IF: 04.800Volume 16, Issue 7No.50Composition and Characterization of the Different Lipoproteins in Overweight/Obese Children vs. Normal-Weight Children超重/肥胖儿童与正常体重儿童不同脂蛋白的组成与特征DOI: 10.3390/biom16070927 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.51The Horizon Ahead: Emerging Adjunctive Therapies for Type 1 Diabetes地平线在前：1型糖尿病新兴辅助疗法DOI: 10.1016/j.ecl.2026.04.012 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.52Expectations and Experiences: What People with Type 1 Diabetes Really Want from Adjunctive Therapies期望与体验：1型糖尿病患者对辅助治疗的真实需求DOI: 10.1016/j.ecl.2026.04.011 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.53Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白抑制剂在1型糖尿病中的联合应用：为何、何时及如何？——联合这两种辅助药物的原理与临床场景探讨DOI: 10.1016/j.ecl.2026.04.009 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.54Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes1型糖尿病成人患者安全使用钠-葡萄糖共转运蛋白抑制剂的临床指导DOI: 10.1016/j.ecl.2026.04.013 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.55Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes成人1型糖尿病患者安全使用胰高血糖素样肽-1受体激动剂的临床指导DOI: 10.1016/j.ecl.2026.04.006 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.56Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes连续酮体监测的未来及其在1型糖尿病中安全使用钠-葡萄糖协同转运蛋白2抑制剂的效用DOI: 10.1016/j.ecl.2026.04.005 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.57Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes钠-葡萄糖共转运蛋白抑制剂、胰高血糖素样肽-1受体激动剂和盐皮质激素受体阻滞剂在1型糖尿病患者中心肾保护的新证据DOI: 10.1016/j.ecl.2026.04.007 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.58Current State of Cardiorenal Disease in People with Type 1 Diabetes1型糖尿病患者心肾疾病的现状DOI: 10.1016/j.ecl.2026.04.004 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.59GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 DiabetesGLP-1受体激动剂可能减少新发1型糖尿病的胰岛素需求DOI: 10.1016/j.ecl.2026.04.010 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.60Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes: What We Know So Far and Future Trials1型糖尿病中每周胰高血糖素样肽-1受体激动剂：已知与未来试验DOI: 10.1016/j.ecl.2026.04.003 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.61Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next每日胰高血糖素样肽-1受体激动剂在1型糖尿病中的应用：我们学到了什么以及下一步是什么DOI: 10.1016/j.ecl.2026.04.002 Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.62Beyond Insulin: Why Type 1 Diabetes Mellitus Needs More?超越胰岛素：1型糖尿病为何需要更多？DOI: 10.1016/j.ecl.2026.04.001 Biochem Biophys Res Commun IF: 02.200Volume 830, Issue No.63Exploring the therapeutic versatility and multitarget pharmacological potential of acyl hydrazone-hydrazide scaffolds酰腙-酰肼骨架的治疗多功能性与多靶点药理潜力探索DOI: 10.1016/j.bbrc.2026.154217 Eur J Oral Sci IF: 01.800Ahead of Print.No.64Glutamate, its relation to periodontitis, diabetes and cognition before and after scaling and root planing谷氨酸及其与牙周炎、糖尿病和认知的关系：刮治和根面平整前后的变化DOI: 10.1111/eos.70128 Primary care diabetes IF: 02.300Ahead of Print.No.65Metformin and sleep health in older adults with type 2 diabetes: Mechanisms, clinical evidence, and future directions, a narrative review二甲双胍与老年2型糖尿病患者的睡眠健康：机制、临床证据和未来方向——一项叙述性综述DOI: 10.1016/j.pcd.2026.07.012 Spectrochim Acta A Mol Biomol Spectrosc IF: 04.600Ahead of Print.No.66Biophysical and computational insights into the activation mechanism of α-glucosidase by aromatic organophosphate esters芳香族有机磷酸酯激活α-葡萄糖苷酶的生物物理与计算机制研究DOI: 10.1016/j.saa.2026.128498 European journal of haematology IF: 02.300Ahead of Print.No.67SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple MyelomaSGLT-2抑制剂与多发性骨髓瘤风险降低相关DOI: 10.1111/ejh.70274 South Dakota journal of medicineVolume 79, Issue suppl 5No.68Abstract: The Preeclampsia Mimic: A Case Report of Cyclic Cushing's Disease Unmasked in the Postpartum Period子痫前期的模仿者：产后揭开的周期性库欣病病例报告https://pubmed.ncbi.nlm.nih.gov/42526011 Heart, Lung and Circulation IF: 02.200Ahead of Print.No.69Cost-Effectiveness of Radiofrequency Renal Denervation for Resistant Hypertension in Australia射频消融肾去神经术治疗澳大利亚难治性高血压的成本效益分析DOI: 10.1016/j.hlc.2026.04.006 Plant foods for human nutrition IF: 03.600Volume 81, Issue 3No.70Phytochemical Characterization and Gut Microbiota Modulation by Berry Cactus Juice Concentrate in a High-Fat Diet-Induced Metabolic Syndrome Rat Model浆果仙人掌果汁浓缩物在高脂饮食诱导的代谢综合征大鼠模型中的植物化学特征及肠道菌群调节作用DOI: 10.1007/s11130-026-01552-7 Journal of ethnopharmacology IF: 05.400Ahead of Print.No.711-Deoxynojirimycin attenuates diabetic cardiomyopathy via PI3K/AKT-mediated mitochondrial protection and anti-apoptosis1-脱氧野尻霉素通过PI3K/AKT介导的线粒体保护与抗凋亡作用减轻糖尿病心肌病DOI: 10.1016/j.jep.2026.122254 The journal of neuroscience : IF: 04.000Volume 46, Issue 30No.72GABAergic Signaling from Arginine Vasopressin Neurons in the Suprachiasmatic Nucleus Is Essential for Maintaining the Estrous Cycle in Mice视交叉上核精氨酸加压素神经元的GABA能信号对维持小鼠发情周期至关重要DOI: 10.1523/JNEUROSCI.2328-25.2026 J Pediatr Hematol Oncol IF: 00.900Ahead of Print.No.73Cardiometabolic Risk and Awareness of Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer: A Population-Based Study儿童癌症幸存者中蒽环类药物相关心脏毒性的心脏代谢风险与认知：一项基于人群的研究DOI: 10.1097/MPH.0000000000003245 Int J Nurs Stud IF: 07.100Ahead of Print.No.74Associations of accelerometer-derived daily step counts with future health risks: A phenome-wide association study among over 60,000 UK adults加速度计测量的每日步数与未来健康风险的关联：一项超过6万名英国成年人的全表型组关联研究DOI: 10.1016/j.ijnurstu.2026.105638 Placenta IF: 02.500Ahead of Print.No.75The role and mechanism of S1PR2 in endothelial dysfunction and aortic lesions during gestational diabetes mellitusS1PR2在妊娠期糖尿病内皮功能障碍和主动脉病变中的作用及机制DOI: 10.1016/j.placenta.2026.07.010 Diabetes & metabolic syndrome IF: 03.400Ahead of Print.No.76Increasing trend in prediabetes and obesity among adolescent school children in Chennai city in Southern India印度南部金奈市青少年学童中糖尿病前期和肥胖的增加趋势DOI: 10.1016/j.dsx.2026.103457 Am J Physiol Cell Physiol IF: 04.700Ahead of Print.No.77SGLT2 Inhibitors as Modulators of Mitochondrial Ion Transport and ER-Mitochondria Crosstalk in Diabetic CardiomyopathySGLT2抑制剂作为糖尿病心肌病中线粒体离子转运和内质网-线粒体串扰的调节剂DOI: 10.1152/ajpcell.00230.2026 South Dakota journal of medicineVolume 79, Issue suppl 5No.78Abstract: Expanding Access to Vascular Care Using BlueDop Vascular Expert: A Prospective Cohort Study使用BlueDop血管专家扩大血管护理的可及性：一项前瞻性队列研究https://pubmed.ncbi.nlm.nih.gov/42526018 South Dakota journal of medicineVolume 79, Issue suppl 5No.79Abstract: Incidence of Pathogens in First Episode of Diabetic Foot Infections and Frequency of Empiric Coverage of Pathogens in Emergency Department and on Hospital Admission: A Retrospective Cohort Study首次糖尿病足感染病原体发生率及急诊科和入院时经验性覆盖频率：一项回顾性队列研究https://pubmed.ncbi.nlm.nih.gov/42526017 South Dakota journal of medicineVolume 79, Issue suppl 5No.80Abstract: Normal Serum IgG4 in Biopsy Proven IgG4 Related Hypophysitis: A Case Report活检证实的IgG4相关垂体炎中血清IgG4正常：一例病例报告https://pubmed.ncbi.nlm.nih.gov/42526010 South Dakota journal of medicineVolume 79, Issue suppl 5No.81Abstract: Unexplained Microcytosis in a 40-Year-Old Male: Case Report of a Missed Opportunity for Early Colorectal Cancer Diagnosis一名40岁男性不明原因小细胞增多症：错失早期结直肠癌诊断机会的病例报告https://pubmed.ncbi.nlm.nih.gov/42525992 South Dakota journal of medicineVolume 79, Issue suppl 5No.82Abstract: Perioperative Anesthetic Outcomes and Holding Practices in Patients Using GLP-1 Receptor Agonists: A Retrospective Cohort Study使用GLP-1受体激动剂患者的围手术期麻醉结局与停药实践：一项回顾性队列研究https://pubmed.ncbi.nlm.nih.gov/42525985 Hum Vaccin Immunother IF: 03.500Volume 22, Issue 1No.83Respiratory syncytial virus disease burden in adults aged ≥50 years old: A retrospective national surveillance database analysis in Mexico (2015-2023)墨西哥50岁及以上成人呼吸道合胞病毒疾病负担：一项基于国家监测数据库的回顾性分析（2015-2023）DOI: 10.1080/21645515.2026.2702188 Neurology IF: 08.500Volume 107, Issue 4No.84Association of Sugar Restriction in Utero Through Age 2 Years on Dementia Risk Later in Life从子宫内到两岁期间的糖限制与晚年痴呆风险的关系DOI: 10.1212/WNL.0000000000218313 Diabetes care IF: 16.600Ahead of Print.No.85Diagnostic Tools to Establish the Presence of Peripheral Arterial Disease in People With Diabetes (DMPAD): A Multicenter Comparative Diagnostic Accuracy Study糖尿病患者外周动脉疾病诊断工具的准确性：一项多中心比较诊断准确性研究DOI: 10.2337/dc25-1693 Science advances IF: 12.500Volume 12, Issue 31No.86Altered Gi signaling in enteroendocrine K cells in vivo causes pronounced changes in glucose homeostasis肠内分泌K细胞中Gi信号改变导致葡萄糖稳态显著变化DOI: 10.1126/sciadv.aeb9805 PloS one IF: 02.600Volume 21, Issue 7No.87Real‑world analysis of Macular Oedema associated with Paclitaxel Formulations using the Japanese Adverse Drug Event Report database使用日本不良药物事件报告数据库对紫杉醇制剂相关黄斑水肿的真实世界分析DOI: 10.1371/journal.pone.0354959 PloS one IF: 02.600Volume 21, Issue 7No.88Association between occupational hearing loss and predicted 10 year cardiovascular risk among middle aged industrial workers职业性听力损失与中年产业工人预测10年心血管风险之间的关联DOI: 10.1371/journal.pone.0354726 PloS one IF: 02.600Volume 21, Issue 7No.89Social determinants of health and postnatal wellbeing among women with type 2 diabetes in Thailand: An explanatory sequential mixed-methods study protocol泰国2型糖尿病女性健康社会决定因素与产后幸福感：一项解释性序贯混合方法研究方案DOI: 10.1371/journal.pone.0354735 Ther Adv Respir Dis IF: 03.000Volume 20, Issue No.90Surgical management of refractory massive hemoptysis from pulmonary artery pseudoaneurysm due to Streptococcus constellatus: a rare case report and literature review链球菌致肺动脉假性动脉瘤难治性大咯血的外科治疗：一例罕见病例报告及文献综述DOI: 10.1177/17534666261455473 Journal of family nursing IF: 02.900Ahead of Print.No.91Parents' Experiences and Perceived Benefits of a Parent Program in Pediatric Type 1 Diabetes儿科1型糖尿病家长项目的体验与感知获益DOI: 10.1177/10748407261464914 Cell reports IF: 06.900Ahead of Print.No.92Organelle proteomics of human, neonatal pig, healthy and diabetic mouse islets人类、新生猪、健康及糖尿病小鼠胰岛的细胞器蛋白质组学DOI: 10.1016/j.celrep.2026.117751 Proc Natl Acad Sci U S A IF: 09.100Volume 123, Issue 31No.93A posttranslational modification of fimbriae drives pathogenicity in Klebsiella pneumoniae菌毛的翻译后修饰驱动肺炎克雷伯菌的致病性DOI: 10.1073/pnas.2611142123 Int J Epidemiol IF: 05.900Volume 55, Issue 4No.94Gestational age at birth and the risk of disability pension in early adulthood: a whole-population register study of people born in Finland in 1987-90出生胎龄与成年早期残疾抚恤金风险：一项基于芬兰1987-90年出生人群的全人口登记研究DOI: 10.1093/ije/dyag127 Eur J Anaesthesiol IF: 06.800Ahead of Print.No.95Specific neurotoxicity of local anaesthetics revisited: An evidence-based narrative review局麻药特异性神经毒性再探讨：一项基于证据的叙述性综述DOI: 10.1097/EJA.0000000000002461 Diabetologia IF: 10.200Volume 30, Issue 7No.96Blood flow in the foot, polyneuropathy and foot ulceration in diabetes mellitus糖尿病足部血流、多发性神经病变与足部溃疡DOI: 10.1007/BF00279614 British medical journalVolume 294, Issue 6576No.97Clinically apparent eating disorders in young diabetic women: associations with painful neuropathy and other complications年轻糖尿病女性中临床明显的进食障碍：与疼痛性神经病变及其他并发症的关联DOI: 10.1136/bmj.294.6576.859 JMIR formative research IF: 02.100Volume 10, Issue No.98Evaluating the Impact and Practicality of a National Digital Intervention for Type 2 Diabetes Mellitus: Single-Arm Nonrandomized Pilot Trial评估全国性2型糖尿病数字干预的影响和实用性：单臂非随机试点试验DOI: 10.2196/94551 The Lancet Microbe IF: 20.400Ahead of Print.No.99State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges全球结核病流行现状：负担、世界卫生组织终结结核病战略目标进展及系统性挑战DOI: 10.1016/j.lanmic.2026.101433 EJPC IF: 07.500Ahead of Print.No.100Hypertension awareness, treatment, and control in coronary heart disease patients: results of the EUROASPIRE V survey conducted in 27 countries冠心病患者高血压知晓、治疗和控制：EUROASPIRE V 调查在27个国家的结果DOI: 10.1093/eurjpc/zwag377 Lancet Diabetes Endocrinol IF: 41.800Ahead of Print.No.101Energy drink ban: putting children's health first能量饮料禁令：将儿童健康置于首位DOI: 10.1016/S2213-8587(26)00195-6 Nutrients IF: 05.000Volume 18, Issue 14No.102Supplementation of γ-Aminobutyric Acid as a Functional Nutrientγ-氨基丁酸作为功能性营养素的补充DOI: 10.3390/nu18142389 Endocrine research IF: 01.800Volume 51, Issue 3No.103The interaction between eGDR and visceral adiposity in renal function decline among middle-aged and elderly diabetes patients: findings from a nationwide Chinese cohort中老年糖尿病患者葡萄糖利用率与内脏脂肪对肾功能下降的交互作用：一项全国性中国队列研究结果DOI: 10.1080/07435800.2026.2671747 Medicina IF: 02.400Volume 62, Issue 7No.104Prevalence of ABO Blood Groups and Their Relationship with Vascular Access Thrombosis and Mortality in Hemodialysis PatientsABO血型在血液透析患者中的分布及其与血管通路血栓形成和死亡率的关系DOI: 10.3390/medicina62071227 Molecules IF: 04.600Volume 31, Issue 14No.105Queen of Spices, Cardamom (Elettaria cardamomum (L.) Maton, Zingiberaceae)-In Vitro Assessment of Biological Potential香料之后，小豆蔻（Elettaria cardamomum (L.) Maton，姜科）的体外生物学潜力评估DOI: 10.3390/molecules31142430 Research squareVolume 0, Issue No.106Primary healthcare system readiness for the prevention and management of non- communicable diseases in Nepal尼泊尔初级卫生保健系统对非传染性疾病预防和管理的准备情况DOI: 10.21203/rs.3.rs-9699438/v1 Curēus IF: 01.300Volume 18, Issue 6No.107Workplace Environment and Lifestyle Factors Associated With Hyperuricemia Risk Among Male Manufacturing Workers: A Cross-Sectional Study at a Single Company in Japan日本某制造企业男性工人高尿酸血症风险相关的工作环境与生活方式因素：一项单公司横断面研究DOI: 10.7759/cureus.111627 EJPC IF: 07.500Ahead of Print.No.108Global Trends in Key Modifiable Cardiovascular Risk Factors: A Joinpoint Analysis Across WHO Regions (1990-2022)全球主要可改变心血管危险因素趋势：世界卫生组织区域的连接点分析（1990-2022）DOI: 10.1093/eurjpc/zwag401 bioRxivVolume 0, Issue No.109Effect of Immunosuppressive Drugs on Glucose-Stimulated Insulin Secretion: Concentration-Response Studies in Dynamic Perifusion Assays免疫抑制药物对葡萄糖刺激的胰岛素分泌的影响：动态灌流测定中的浓度-反应研究DOI: 10.64898/2026.07.09.737557 Exp Ther Med IF: 02.300Volume 32, Issue 3No.110Ubiquitin-driven regulation of immune checkpoints in lung cancer: Mechanisms and therapeutic implications (Review)泛素驱动的肺癌免疫检查点调控：机制与治疗意义（综述）DOI: 10.3892/etm.2026.13243 Molecular biology reports IF: 02.800Volume 53, Issue 1No.111Insulin pathway components and insulin effects on rho kinase in rat colon大鼠结肠中胰岛素通路组分及胰岛素对Rho激酶的影响DOI: 10.1007/s11033-026-12420-7 Advanced pharmaceutical bulletin IF: 04.100Volume 16, Issue 1No.112Clinical Studies Using Intranasal Therapies for Parkinson's Disease: A Review鼻内疗法治疗帕金森病的临床研究综述DOI: 10.34172/apb.025.46111 Front Sports Act Living IF: 02.600Volume 8, Issue No.113Lifelong football training influences miR-1303 serum expression and human breast cancer MCF-7 cells motility: a pilot study终身足球训练影响miR-1303血清表达及人乳腺癌MCF-7细胞运动能力：一项初步研究DOI: 10.3389/fspor.2026.1727357 Acta Biochimica Polonica IF: 01.700Volume 73, Issue No.114Beyond biochemistry: multiparametric ultrasound parameters and their molecular correlates in cardio-renal-metabolic syndrome超越生物化学：心肾代谢综合征的多参数超声参数及其分子相关性DOI: 10.3389/abp.2026.16873 Research squareVolume 0, Issue No.115Unbiased discovery of autoreactive type 1 diabetes T-cell receptors that bind specific hybrid insulin peptides无偏发现结合特定杂交胰岛素肽的1型糖尿病自身反应性T细胞受体DOI: 10.21203/rs.3.rs-10074672/v1 bioRxivVolume 0, Issue No.116Supplementation via DAF-16 and pnk-1 driven pantothenate-coenzyme A flux improves disease related stress resistance in C. elegans通过DAF-16和pnk-1驱动的泛酸-辅酶A通量补充改善线虫疾病相关应激抵抗DOI: 10.64898/2026.07.08.737381 bioRxivVolume 0, Issue No.117The NBSGW RIP-DTR Mouse: An Integrated Platform for Diabetes Induction, Human Immune Reconstitution and Transplantation StudiesNBSGW RIP-DTR小鼠：用于糖尿病诱导、人免疫重建和移植研究的整合平台DOI: 10.64898/2026.07.10.737744 bioRxivVolume 0, Issue No.118Generation of hypoimmunogenic gastric insulin-secreting organoids低免疫原性胃胰岛素分泌类器官的生成DOI: 10.64898/2026.07.08.736836 bioRxivVolume 0, Issue No.119Alveolar Epithelial Cell Loss of the Mitochondrial Regulator TFAM Drives Progressive Lung Fibrosis肺泡上皮细胞线粒体调控因子TFAM缺失驱动进行性肺纤维化DOI: 10.64898/2026.05.28.728065 bioRxivVolume 0, Issue No.120Metabolic responses to physiological stressors assessed using continuous glucose monitoring integrated with indirect calorimetry in mice利用连续血糖监测结合间接测热法评估小鼠对生理应激源的新陈代谢反应DOI: 10.64898/2026.07.13.738308 bioRxivVolume 0, Issue No.121Munc18 binds to and organizes membrane-bound acceptor Q-SNARE complexes in a fashion that depends on the membrane's lipid compositionMunc18以依赖于膜脂质组成的方式结合并组织膜结合的受体Q-SNARE复合物DOI: 10.64898/2026.07.14.738512 bioRxivVolume 0, Issue No.122FAIM Inhibits Insulin Amyloidogenesis through a Noncanonical Aggregation PathwayFAIM通过非经典聚集途径抑制胰岛素淀粉样变性DOI: 10.64898/2026.07.13.738277 bioRxivVolume 0, Issue No.123Gene model for the ortholog of raptor in Drosophila eugracilis果蝇Drosophila eugracilis中raptor直系同源基因的基因模型DOI: 10.64898/2026.07.10.737807 bioRxivVolume 0, Issue No.124Gene model for the ortholog of raptor in Drosophila erectaDrosophila erecta中raptor直系同源基因模型DOI: 10.64898/2026.07.09.737526 bioRxivVolume 0, Issue No.125Gene model for the ortholog of DENR in Drosophila grimshawiDrosophila grimshawi中DENR直系同源基因模型DOI: 10.64898/2026.07.14.738501 Frontiers in medicine IF: 03.000Volume 13, Issue No.126Admission ECG-derived resting heart rate and in-hospital mortality after acute stroke: a multicenter retrospective cohort study入院心电图衍生的静息心率与急性卒中后住院死亡率：一项多中心回顾性队列研究DOI: 10.3389/fmed.2026.1845558 CNS neuroscience & therapeutics IF: 05.000Volume 32, Issue 8No.127Prediction Model for Mild Cognitive Impairment in Older Chinese Patients With Cerebral Small Vessel Disease Based on XGBoost Algorithms and Shapley Additive Explanations基于XGBoost算法和Shapley加法解释的中国老年脑小血管病患者轻度认知障碍预测模型DOI: 10.1002/cns.71044 Research squareVolume 0, Issue No.128Integrated Myocardial and Plasma Lipidome Across the Human Obesity-Heart Failure Spectrum人类肥胖-心力衰竭谱系中整合的心肌和血浆脂质组DOI: 10.21203/rs.3.rs-10157404/v1 Research squareVolume 0, Issue No.129Reduced LACTB expression in myeloid cells is associated with elevated succinylcarnitine and reduced Alzheimer's disease risk髓系细胞中LACTB表达降低与琥珀酰肉碱升高及阿尔茨海默病风险降低相关DOI: 10.21203/rs.3.rs-10216155/v1 RSC advances IF: 04.600Ahead of Print.No.130High-affinity inclusion of sitagliptin by cucurbit[7]uril: structural insights and fluorescence-based sensing西格列汀与葫芦[7]脲的高亲和力包合：结构洞察与荧光传感DOI: 10.1039/d6ra05123e J Diabetes Metab Disord IF: 01.600Volume 25, Issue 2No.131Statin Use Patterns among hypertensive Patients in a population-based study基于人群的高血压患者他汀类药物使用模式研究DOI: 10.1007/s40200-026-02018-y JCEM case reportsVolume 4, Issue 9No.132Metastatic large cell neuroendocrine carcinoma: a rare cause of hypopituitarism转移性大细胞神经内分泌癌：垂体功能减退症的罕见病因DOI: 10.1210/jcemcr/luag205 Case reports in neurology IF: 00.600Volume 18, Issue 1No.133Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss体重下降致足下垂：替尔泊肽介导减重后跷二郎腿引起腓神经麻痹的病例系列DOI: 10.1159/000552890 Scientific reports IF: 03.900Volume 16, Issue 1No.134Association of the cardiometabolic index and depressive symptoms with cardiovascular disease in cardiovascular-kidney-metabolic syndrome stages 0-3: A prospective cohort study心脏代谢指数与抑郁症状对心血管-肾脏-代谢综合征0-3期患者心血管疾病风险的关联：一项前瞻性队列研究DOI: 10.1038/s41598-026-63006-z JAMA surgery IF: 14.900Ahead of Print.No.135End-Organ Damage Associated With Primary Hyperparathyroidism原发性甲状旁腺功能亢进症相关的终末器官损害DOI: 10.1001/jamasurg.2026.3051 The oncologist IF: 04.200Ahead of Print.No.136Targeted Therapies in the Management of Advanced Medullary Thyroid Cancer晚期甲状腺髓样癌的靶向治疗DOI: 10.1093/oncolo/oyag300 Ophthalmic Physiol Opt IF: 02.400Ahead of Print.No.137Exploring Characteristics and Systemic Health Links in Myopic Australian Adults澳大利亚近视成年人的特征及与全身健康的关系探索DOI: 10.1007/s44402-026-00157-6 Med Biol Eng Comput IF: 02.600Ahead of Print.No.138Neural networks improve repeatability of intravoxel incoherent motion (IVIM) parameter estimation in pancreatic diffusion-weighted MRI神经网络提高胰腺弥散加权MRI中体素内不相干运动参数估计的可重复性DOI: 10.1007/s11517-026-03637-6 Radiol Phys Technol IF: 01.500Ahead of Print.No.139Content-based retrieval of fundus images and diabetic retinopathy detection using variants of local texture features基于局部纹理特征变体的眼底图像内容检索与糖尿病视网膜病变检测DOI: 10.1007/s12194-026-01106-1 Appl Biochem Biotechnol IF: 03.300Ahead of Print.No.140Estimated Binding Affinities of Polyphenolic Compounds into the Human Peroxiredoxin 5 and the SARS-CoV-2 main Protease Binding Sites: In Silico Approach多酚化合物与人过氧化物酶5及SARS-CoV-2主蛋白酶结合位点的结合亲和力估算：计算机模拟方法DOI: 10.1007/s12010-026-05852-1 GeroScience IF: 05.400Ahead of Print.No.141Longitudinal association between dietary quality trajectories and cognitive frailty in older adults: a 12-year study of the TIGER cohort老年人膳食质量轨迹与认知衰弱的前瞻性关联：TIGER队列12年研究DOI: 10.1007/s11357-026-02413-6 Diabetologia IF: 10.200Ahead of Print.No.142A narrative systematic review of definitions and diagnostic criteria for disordered eating and eating disorders in type 1 diabetes1型糖尿病中进食障碍和饮食失调的定义与诊断标准的叙述性系统综述DOI: 10.1007/s00125-026-06805-3 Acta diabetologica IF: 02.900Ahead of Print.No.143Continuous glucose monitoring and glycaemic variability in acute ischaemic stroke: a systematic review with narrative synthesis急性缺血性卒中中的持续葡萄糖监测与血糖变异性：系统综述与叙述性综合DOI: 10.1007/s00592-026-02766-6 Acta diabetologica IF: 02.900Ahead of Print.No.144Immune cell-derived circulating extracellular vesicles mediate metabolic dysfunction in preclinical and clinical type 1 diabetes免疫细胞来源的循环细胞外囊泡介导临床前和临床1型糖尿病的代谢功能障碍DOI: 10.1007/s00592-026-02769-3 Acta diabetologica IF: 02.900Ahead of Print.No.145Migration background and diabetes technology use at diagnosis and follow-up in children and adolescents with type 1 diabetes: a single-centre study移民背景与1型糖尿病儿童及青少年在诊断和随访时糖尿病技术使用的关联：一项单中心研究DOI: 10.1007/s00592-026-02758-6 Revista Brasileira de Enfermagem IF: 01.200Volume 79, Issue No.146Impact of COVID-19 pandemic on families of children and adolescents with diabetes: maternal perspectiveCOVID-19大流行对糖尿病儿童和青少年家庭的影响：母亲视角DOI: 10.1590/0034-7167-2025-0122 Arquivos de gastroenterologiaVolume 63, Issue No.147USE OF THE FIBROSIS-4 INDEX FOR SCREENING LIVER FIBROSIS IN PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS AND GLUCOSE METABOLISM DISORDERS纤维化-4指数在人类免疫缺陷病毒感染合并糖代谢异常患者中筛查肝纤维化的应用DOI: 10.1590/S0004-2803.24612026-003 Internal medicine journal IF: 01.500Ahead of Print.No.148Regulatory standardisation to improve the safety of continuous glucose monitoring systems in Australia and New Zealand: joint ADS/ADEA/ADIPS/ANZSPED/NZSSD statement澳大利亚和新西兰持续葡萄糖监测系统监管标准化以提升安全性：ADS/ADEA/ADIPS/ANZSPED/NZSSD联合声明DOI: 10.1111/imj.70586 Adv Clin Exp Med IF: 01.900Ahead of Print.No.149Correlation between dental, bone, and chronological age in children with growth hormone deficiency生长激素缺乏儿童牙齿、骨骼和实际年龄的相关性DOI: 10.17219/acem/211566 AJR IF: 06.100Ahead of Print.No.150Operationalizing Diabetic Preparation for [18F]FDG PET/CT糖尿病患者[18F]FDG PET/CT检查准备的规范化操作DOI: 10.2214/AJR.26.35623 AJR IF: 06.100Ahead of Print.No.151Screening for Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence, Challenges, and the Role of Imaging-From the AJR Special Series on Screening代谢功能障碍相关脂肪性肝病纤维化筛查：证据、挑战与影像学作用——来自AJR筛查特刊DOI: 10.2214/AJR.26.34836 Advanced science IF: 14.100Ahead of Print.No.152Stage-Adaptive Janus Microneedle System for Redox-Immune Regulation and Mitochondrial Protection in Infected Diabetic Wound Healing阶段自适应Janus微针系统用于感染性糖尿病伤口愈合中的氧化还原-免疫调节和线粒体保护DOI: 10.1002/advs.202600076 Kidney diseases IF: 03.100Volume 12, Issue 1No.153Genetic Insights into Persistent Hypouricemia in Adults: Novel Findings from an Adult Nephrogenetic Clinic成人持续性低尿酸血症的遗传学见解：来自成人肾脏遗传学诊所的新发现DOI: 10.1159/000552657 Curēus IF: 01.300Volume 18, Issue 6No.154Treatment-Induced Neuropathy of Diabetes: Focus on Autonomic Neuropathy糖尿病治疗诱发的神经病变：关注自主神经病变DOI: 10.7759/cureus.111651 Cardiology Research IF: 01.400Volume 17, Issue 4No.155Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter RegistryPristine+™ 依维莫司洗脱钴铬冠状动脉支架系统：一项前瞻性多中心注册研究DOI: 10.14740/cr2230 Indian J Occup Environ Med IF: 00.800Volume 30, Issue 2No.156Synergistic Effects of Environmental Noise and Aging on Hearing Loss: A Comparative Analysis of Elderly Residents Near Powerloom Industries环境噪声与老龄化对听力损失的协同效应：动力织机产业附近老年居民的对比分析DOI: 10.4103/ijoem.ijoem_94_25 Frontiers in genetics IF: 02.800Volume 17, Issue No.157Genotype-based severity scoring system in Wolfram Syndrome: correlation with onset of cardinal symptoms and WFS1 gene variant types基于基因型的Wolfram综合征严重程度评分系统：与主要症状发病年龄及WFS1基因变异类型的相关性DOI: 10.3389/fgene.2026.1839135 Curēus IF: 01.300Volume 18, Issue 6No.158Design and Early Implementation Outcomes of a Mobile Health-Enabled Social Support Intervention for Adults Living With HIV and Type 2 Diabetes in Uganda乌干达HIV合并2型糖尿病成人患者移动健康社会支持干预的设计与早期实施结果DOI: 10.7759/cureus.111640 Indian J Occup Environ Med IF: 00.800Volume 30, Issue 2No.159Women's Health in Agriculture: A Cross-Sectional Survey Assessing Occupational Hazards and Health Outcomes Among Women Agricultural Workers农业女性健康：一项评估女性农业工人职业危害与健康结局的横断面调查DOI: 10.4103/ijoem.ijoem_175_25 Curēus IF: 01.300Volume 18, Issue 6No.160Management of Emphysematous Cystitis in the Intensive Care Unit重症监护室中气肿性膀胱炎的管理DOI: 10.7759/cureus.111654 Frontiers in surgery IF: 01.800Volume 13, Issue No.161Nonlinear relationship and threshold effect of D-dimer on preoperative deep vein thrombosis in patients with ankle fractures: a retrospective study踝关节骨折患者D-二聚体与术前深静脉血栓形成的非线性关系及阈值效应：一项回顾性研究DOI: 10.3389/fsurg.2026.1856179 JBMR plus IF: 02.400Volume 10, Issue 8No.162Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL维生素K与维生素D状态对骨密度的相互关系研究：来自VITamin D and OmegA-3 TriaL的结果DOI: 10.1093/jbmrpl/ziag110 Acta Cardiologica Sinica IF: 01.800Volume 42, Issue 4No.163Impact of Preoperative Cardiac Evaluation and Recommendations on Morbidity and Mortality in Patients Undergoing Elective Non-Cardiac Interventions: A Retrospective Cohort Study择期非心脏手术患者术前心脏评估与建议对发病率和死亡率的影响：一项回顾性队列研究DOI: 10.6515/ACS.202607_42(4).20251206A British Journal of CardiologyVolume 33, Issue 1No.164SGLT2 inhibitors in frailty: a review of current evidence, and clinical recommendationsSGLT2抑制剂在衰弱患者中的应用：当前证据与临床建议综述DOI: 10.5837/bjc.2026.002 Cardiology Research IF: 01.400Volume 17, Issue 4No.165Comparative Efficacy and Safety of P2Y12 Inhibitors in Patients With Diabetes Mellitus and Coronary Artery Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled TrialsP2Y12抑制剂在糖尿病合并冠状动脉疾病患者中的有效性与安全性比较：随机对照试验的系统评价与网络荟萃分析DOI: 10.14740/cr2254 Frontiers in public health IF: 03.400Volume 14, Issue No.166Association between MDROs colonization and subsequent infections in ICU patients: a retrospective cohort study重症监护病房患者多重耐药菌定植与后续感染的相关性：一项回顾性队列研究DOI: 10.3389/fpubh.2026.1863334 Acta Cardiologica Sinica IF: 01.800Volume 42, Issue 4No.167Cardiovascular Disease Management Consensus in Kidney Transplantation Recipients肾移植受者心血管疾病管理共识DOI: 10.6515/ACS.202607_42(4).20260204A Advanced pharmaceutical bulletin IF: 04.100Volume 16, Issue 1No.168The Effects of Coenzyme Q10 Supplementation on the Contrast Sensitivity Score, Biomarkers of Oxidative Stress, Inflammation, and β-Secretase Activity in the Blood and the Correlation Among these Factors in Diabetic Retinopathy Patients; Clinical Trial辅酶Q10补充对糖尿病视网膜病变患者对比敏感度评分、氧化应激、炎症和β-分泌酶活性生物标志物的影响及其相关性：临床试验DOI: 10.34172/apb.46420 Geohealth IF: 03.800Volume 10, Issue 7No.169Heat and Dust Impacts on the Health of Refugees in Zaatari Refugee Camp热浪与沙尘对扎塔里难民营难民健康的影响DOI: 10.1029/2025GH001687 Frontiers in pharmacology IF: 04.800Volume 17, Issue No.170Correction: Impact of the Warburg effect on nucleotide homeostasis in human retinal endothelial cells and its relevance to proliferative diabetic retinopathy更正：Warburg效应对人视网膜内皮细胞核苷酸稳态的影响及其与增殖性糖尿病视网膜病变的相关性DOI: 10.3389/fphar.2026.1907892 Front Cell Infect Microbiol IF: 04.800Volume 16, Issue No.171From serum inflammatory markers to fluid, tissue, and molecular assays: current advances in the laboratory diagnosis of bone and joint infections从血清炎症标志物到体液、组织和分子检测：骨与关节感染实验室诊断的最新进展DOI: 10.3389/fcimb.2026.1865643 Digital health IF: 03.300Volume 12, Issue No.172Evidence integration: The transformative role of artificial intelligence in maternal health证据整合：人工智能在孕产妇健康中的变革性作用DOI: 10.1177/20552076261473727 Frontiers in public health IF: 03.400Volume 14, Issue No.173Factors associated with tuberculosis patient delay: a meta-analysis结核病患者就诊延迟相关因素：一项荟萃分析DOI: 10.3389/fpubh.2026.1832410 Frontiers in medicine IF: 03.000Volume 13, Issue No.174Impact of scheduled cesarean sections on non-working days on maternal and neonatal outcomes: a retrospective cohort study based on propensity score matching择期剖宫产安排在非工作日对母婴结局的影响：基于倾向性评分匹配的回顾性队列研究DOI: 10.3389/fmed.2026.1839582 Frontiers in medicine IF: 03.000Volume 13, Issue No.175Levels of vascular endothelial growth factor and filtration surgery outcomes in diabetic patients with acute primary angle closure糖尿病患者急性原发性房角关闭中血管内皮生长因子水平与滤过手术结局的关系DOI: 10.3389/fmed.2026.1867803 Frontiers in neurology IF: 02.800Volume 17, Issue No.176Relationship between hemoglobin glycation index and mild cognitive impairment risk in middle-aged and elderly people: a cohort study from CHARLS 2011-2018中老年人群血红蛋白糖化指数与轻度认知障碍风险的关系：基于CHARLS 2011-2018的队列研究DOI: 10.3389/fneur.2026.1852076 Frontiers in immunology IF: 05.900Volume 17, Issue No.177Exploring macrophage polarization: biological insights, key laboratory techniques and research perspectives探索巨噬细胞极化：生物学见解、关键实验室技术与研究展望DOI: 10.3389/fimmu.2026.1837287 Int J Ophthalmol IF: 01.800Volume 19, Issue 8No.178Vacuolar protein sorting 35 regulates retinal neurovascular function via astrocyte-mediated inflammatory response in a diabetic mouse model液泡蛋白分选35通过星形胶质细胞介导的炎症反应调控糖尿病小鼠视网膜神经血管功能DOI: 10.18240/ijo.2026.08.05 Frontiers in endocrinology IF: 04.600Volume 17, Issue No.179Pre-hospital delay > 7 days independently predicts impaired wound healing in diabetic foot ulcer patients: a 3-year retrospective cohort study院前延迟超过7天独立预测糖尿病足溃疡患者伤口愈合不良：一项3年回顾性队列研究DOI: 10.3389/fendo.2026.1860867 Int J Ophthalmol IF: 01.800Volume 19, Issue 8No.180Silencing SLC31A1 attenuates high glucose plus copper-induced cuproptosis-like signaling, oxidative stress, and barrier dysfunction in human retinal microvascular endothelial cells沉默SLC31A1减轻高糖加铜诱导的人视网膜微血管内皮细胞铜死亡样信号、氧化应激和屏障功能障碍DOI: 10.18240/ijo.2026.08.04 Int J Ophthalmol IF: 01.800Volume 19, Issue 8No.181Neurodegeneration as an early driver and therapeutic target in diabetic retinopathy神经退行性变作为糖尿病视网膜病变的早期驱动因素和治疗靶点DOI: 10.18240/ijo.2026.08.21 Expert review of medical devices IF: 02.700Ahead of Print.No.182Efficacy of targeted neuromodulation treatments: a clinical report靶向神经调控治疗的有效性：一项临床报告DOI: 10.1080/17434440.2026.2709771 Curēus IF: 01.300Volume 18, Issue 6No.183A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders系统评价与荟萃分析：GLP-1受体激动剂在物质使用障碍中的作用DOI: 10.7759/cureus.111641 Curēus IF: 01.300Volume 18, Issue 6No.184Adult Annular Pancreas Presenting With Gastric Outlet Obstruction Following Semaglutide Initiation: A Case Report成人环状胰腺在司美格鲁肽治疗后出现胃出口梗阻：一例病例报告DOI: 10.7759/cureus.111636 Int J Clin Pharm IF: 03.200Ahead of Print.No.185Global burden and future trends of type 2 diabetes mellitus-associated chronic kidney disease: analysis of the Global Burden of Disease Study 20212型糖尿病相关慢性肾脏病的全球负担与未来趋势：基于2021年全球疾病负担研究的分析DOI: 10.1007/s11096-026-02201-4 Cadernos de Saúde Pública IF: 01.800Volume 42, Issue No.186[Impact of the national strategy against obesity and diabetes on the incidence of diabetes in Mexico, 2005-2023]墨西哥国家肥胖与糖尿病策略对糖尿病发病率的影响（2005-2023）DOI: 10.1590/0102-311XES180725 Int J Gen Med IF: 02.000Volume 19, Issue No.187Relationship of Estimated Glomerular Filtration Rate (eGFR) and Neuron-Specific Enolase (NSE) with Cognitive Dysfunction in Type 2 Diabetes Mellitus: A Cross-Sectional Analysis估算肾小球滤过率与神经元特异性烯醇化酶与2型糖尿病认知功能障碍的关系：一项横断面分析DOI: 10.2147/IJGM.S622979 Journal of cancer IF: 03.200Volume 17, Issue 7No.188Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells长期恩格列净治疗（50天）减弱BFTC-909肾盂移行细胞癌细胞的蛋白酶活性、迁移和干性相关表型DOI: 10.7150/jca.132959 Small scienceVolume 6, Issue 7No.189Janus Polymeric Nanorods Inhibit human Amylin Oligomerization and Fibrillation for Potential Type 2 Diabetes TreatmentJanus聚合物纳米棒抑制人胰淀素寡聚化和纤维化用于潜在2型糖尿病治疗DOI: 10.1002/smsc.70326 Curēus IF: 01.300Volume 18, Issue 6No.190Concomitant Diagnosis of Acute Promyelocytic Leukemia and Type 2 Diabetes Mellitus in a Child: Report of a Rare Case儿童急性早幼粒细胞白血病与2型糖尿病同时诊断：一例罕见病例报告DOI: 10.7759/cureus.111647 Frontiers in nutrition IF: 05.100Volume 13, Issue No.191Association between the uric acid to high-density lipoprotein cholesterol ratio and estimated glomerular filtration rate decline in community-managed patients with type 2 diabetes: a retrospective cohort study尿酸与高密度脂蛋白胆固醇比值与社区管理2型糖尿病患者估算肾小球滤过率下降的关联：一项回顾性队列研究DOI: 10.3389/fnut.2026.1879633 Frontiers in medicine IF: 03.000Volume 13, Issue No.192Artificial intelligence-based analysis of retinal vascular changes in the preclinical and early stages of diabetic retinopathy using ultra-widefield fundus imaging: an observational cross-sectional study基于人工智能的超广角眼底成像分析糖尿病视网膜病变临床前期和早期视网膜血管变化：一项观察性横断面研究DOI: 10.3389/fmed.2026.1906162 Frontiers in public health IF: 03.400Volume 14, Issue No.193Burden of metabolic diseases in mainland China from 1990 to 2021: results from the global burden of disease study 20211990年至2021年中国大陆代谢性疾病负担：基于2021年全球疾病负担研究的结果DOI: 10.3389/fpubh.2026.1846594 Frontiers in oncology IF: 03.300Volume 16, Issue No.194Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis2型糖尿病患者使用胰高血糖素样肽-1受体激动剂的癌症结局与生物学机制：系统评价与荟萃分析DOI: 10.3389/fonc.2026.1859759 Frontiers in medicine IF: 03.000Volume 13, Issue No.195Association between glycated hemoglobin and lipid parameters at the time of type 2 diabetes mellitus diagnosis: evidence from a regional population2型糖尿病诊断时糖化血红蛋白与血脂参数的关系：来自区域人群的证据DOI: 10.3389/fmed.2026.1833588 Frontiers in nutrition IF: 05.100Volume 13, Issue No.196A narrative review of dietary patterns in cardiovascular-kidney-metabolic syndrome心血管-肾脏-代谢综合征中饮食模式的叙述性综述DOI: 10.3389/fnut.2026.1799305 Int J Ophthalmol IF: 01.800Volume 19, Issue 8No.197Vision loss and blindness due to type 2 diabetes mellitus among young adults: a global burden study from 1990 to 20212型糖尿病导致的青壮年视力丧失和失明：1990至2021年全球负担研究DOI: 10.18240/ijo.2026.08.15 Frontiers in nutrition IF: 05.100Volume 13, Issue No.198Standardized curcumin formulations in type 2 diabetes mellitus: a precision adjunct strategy targeting bioavailability, glycemic control, and immunometabolic inflammation标准化姜黄素制剂在2型糖尿病中的应用：针对生物利用度、血糖控制和免疫代谢炎症的精准辅助策略DOI: 10.3389/fnut.2026.1874887 Frontiers in oncology IF: 03.300Volume 16, Issue No.199Metabolic comorbidities affect the survival of hepatitis B virus-related hepatocellular carcinoma in Chinese patients: a retrospective cohort study with propensity score matching代谢合并症影响中国乙型肝炎病毒相关肝细胞癌患者的生存：一项倾向评分匹配的回顾性队列研究DOI: 10.3389/fonc.2026.1863272 Frontiers in endocrinology IF: 04.600Volume 17, Issue No.200The effect of type 2 diabetes on the prognosis of community-acquired pneumonia2型糖尿病对社区获得性肺炎预后的影响DOI: 10.3389/fendo.2026.1878364 Analyst IF: 03.300Ahead of Print.No.201Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products同时测定恩格列净和美托洛尔药物剂型的稳定性指示LC-MS/MS方法的开发与验证：强制降解研究及降解产物的计算评估DOI: 10.1039/d6an00707d European psychiatry : IF: 06.700Ahead of Print.No.202Loneliness and social isolation as risk factors for incident depression in type 2 diabetes mellitus: Evidence from a prospective cohort study孤独感与社会隔离作为2型糖尿病新发抑郁风险因素：一项前瞻性队列研究的证据DOI: 10.1192/j.eurpsy.2026.12244 J Diabetes Investig IF: 03.000Ahead of Print.No.203Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients糖化间隙与日本2型糖尿病患者低血糖CGM指标、糖尿病并发症及生活质量的关系DOI: 10.1111/jdi.70403 An Acad Bras Cienc IF: 01.100Volume 98, Issue 2No.204Metformin hydrochloride extended-release tablets: perception of the occurrence of gastrointestinal adverse events and biopharmaceutical evaluation盐酸二甲双胍缓释片：胃肠道不良事件发生感知及生物药剂学评价DOI: 10.1590/0001-3765202620250312 Advanced pharmaceutical bulletin IF: 04.100Volume 16, Issue 1No.205Dual Modulation of Senescence and Immune Checkpoints by Metformin and Dapagliflozin Attenuates Liver Fibrosis in a Thioacetamide-Induced Rat Model二甲双胍与达格列净双重调控衰老和免疫检查点减轻硫代乙酰胺诱导的大鼠肝纤维化DOI: 10.34172/apb.025.46231 bioRxivVolume 0, Issue No.206Phosphoproteomic Insights into TRPV4-AMPK Signaling Axis in the Choroid Plexus Epithelium: Implications for Therapeutic Targeting in Hydrocephalus脉络丛上皮TRPV4-AMPK信号轴的磷酸化蛋白质组学分析：对脑积水治疗靶点的启示DOI: 10.64898/2026.07.13.738282 Asian Pac J Cancer PrevVolume 27, Issue 7No.207The Synergistic Effects of Metformin with Pitavstatin Against MDA-MB-468 Breast Cancer Cells二甲双胍与匹伐他汀联合对MDA-MB-468乳腺癌细胞的协同作用DOI: 10.31557/APJCP.2026.27.7.2705 Diabetologia IF: 10.200Ahead of Print.No.208Cardiac autonomic neuropathy predicts renal decline in type 1 diabetes mellitus: a 15 year follow-up study心脏自主神经病变预测1型糖尿病患者的肾功能下降：一项15年随访研究DOI: 10.1007/s00125-026-06818-y J Clin Biochem Nutr IF: 01.700Volume 79, Issue 1No.209Trace elements in relation to glycemic control and disease complications in children living with type 1 diabetes mellitus微量元素与1型糖尿病儿童血糖控制和并发症的关系DOI: 10.3164/jcbn.26-3 Frontiers in medicine IF: 03.000Volume 13, Issue No.210Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis病例报告：青少年糖尿病酮症酸中毒并发鼻眶脑毛霉菌病DOI: 10.3389/fmed.2026.1847375 Human factors in healthcare IF: 02.200Volume 10, Issue No.211Perceptions of adults with type 1 diabetes mellitus about diabetes management and exercise1型糖尿病成人患者对糖尿病管理和体力活动的看法DOI: 10.1016/j.hfh.2026.100146 J Diabetes Sci Technol IF: 03.700Ahead of Print.No.212A First Exploratory Study of Glycemic Outcomes During Normobaric Hypoxia Simulating Moderate-Altitude Conditions in Men With Type 1 Diabetes Using Automated Insulin Delivery, With Biochemical Comparison to Healthy Individuals模拟中等海拔条件的常压低氧期间使用自动胰岛素输送的1型糖尿病男性血糖结局的首次探索性研究，并与健康个体进行生化比较DOI: 10.1177/19322968261464595 JAMA IF: 55.000Ahead of Print.No.213Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023全球低密度脂蛋白胆固醇升高负担：2023年全球疾病负担研究结果DOI: 10.1001/jama.2026.8628 JAMA IF: 55.000Ahead of Print.No.214Sleep Health and Obesity睡眠健康与肥胖DOI: 10.1001/jama.2026.9551 Pediatric blood & cancer IF: 02.300Ahead of Print.No.215Gabapentin-Associated Respiratory Depression and Eczematous Drug Eruption During Anti-GD2 Immunotherapy in a Child With High-Risk Neuroblastoma高危神经母细胞瘤患儿抗GD2免疫治疗期间加巴喷丁相关性呼吸抑制及湿疹样药疹DOI: 10.1002/1545-5017.70462 Sleep & breathing IF: 02.000Volume 30, Issue 4No.216Relationship between MSpO2 and depressive symptoms in older patients with obstructive sleep apnea: a cross-sectional study老年阻塞性睡眠呼吸暂停患者平均脉搏血氧饱和度与抑郁症状的关系：一项横断面研究DOI: 10.1007/s11325-026-03768-y Endocrinol Metab Clin North Am IF: 04.200Volume 55, Issue 3No.217Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes钠-葡萄糖共转运蛋白抑制剂、肠促胰素受体激动剂（胰高血糖素样肽-1受体激动剂和双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂）及非奈利酮在1型糖尿病中的肾脏保护作用DOI: 10.1016/j.ecl.2026.04.015 Ophthalmology retina IF: 05.700Ahead of Print.No.218Sustained High-Intensity Lipophilic Statin Use and Risk of Age-Related Macular Degeneration: A Target Trial Emulation持续高强度亲脂性他汀类药物使用与年龄相关性黄斑变性风险：一项目标试验模拟研究DOI: 10.1016/j.oret.2026.07.014 Diabetes Res Clin Pract IF: 07.400Ahead of Print.No.219Cardiometabolic profile and cardiorenal complications across BMI categories in type 2 diabetes: A nationwide real-world analysis of over 500,000 patients2型糖尿病患者不同体重指数类别的心代谢特征与心肾并发症：一项基于全国超过50万患者的真实世界分析DOI: 10.1016/j.diabres.2026.113467 The Lancet IF: 88.500Ahead of Print.No.220Psoriasis银屑病DOI: 10.1016/S0140-6736(26)00349-1 J Neonatal Perinatal Med IF: 00.900Ahead of Print.No.221Impact of labor before delivery on necrotizing enterocolitis in very low birth weight infants产前宫缩对极低出生体重儿坏死性小肠结肠炎的影响DOI: 10.1177/19345798261475330 The American surgeon IF: 00.900Ahead of Print.No.222From Debridement to Skin Grafting: Where Fish-Skin Xenografting Fits in Staged Reconstruction of Necrotizing Soft Tissue Infections从清创到植皮：鱼皮异种移植在坏死性软组织感染分期重建中的位置DOI: 10.1177/00031348261474189 J Foot Ankle Res IF: 02.200Volume 19, Issue 3No.223Diabetes Distress in People at Risk for Diabetes-Related Foot Disease in Primary Health Care初级卫生保健中糖尿病相关足病风险人群的糖尿病困扰DOI: 10.1002/jfa2.70194 In Vitro Cell Dev Biol Anim IF: 01.700Ahead of Print.No.224Endothelial cell-derived microRNAs-containing extracellular vesicles and diabetic retinopathy in a mouse model of diabetes内皮细胞来源的含microRNA的细胞外囊泡与糖尿病小鼠模型中的糖尿病视网膜病变DOI: 10.1007/s11626-026-01205-8 Stem cell reviews and reports IF: 04.200Ahead of Print.No.225Harnessing Endogenous Plasticity Rather than Reprogramming of Mature Cells Will Advance Regenerative Medicine, Cancer Treatment and Rejuvenation利用内源性可塑性而非成熟细胞重编程将推动再生医学、癌症治疗和抗衰老发展DOI: 10.1007/s12015-026-11197-3 Aliment Pharmacol Ther IF: 06.700Ahead of Print.No.226Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset临床试验：Resmetirom 与安慰剂在代谢功能障碍相关脂肪性肝炎中的3期试验——纤维化2-3期亚组再分析DOI: 10.1111/apt.70888 Lab animal IF: 03.900Volume 55, Issue 8No.227Retatrutide effects on diabetic rats' cognition瑞他鲁肽对糖尿病大鼠认知功能的影响DOI: 10.1038/s41684-026-01778-7 npj health systemsVolume 3, Issue 1No.228Human-in-the-loop AI predictive digital twin to extend virtual precision diabetes care between visits人机协同人工智能预测性数字孪生模型在就诊间期扩展虚拟精准糖尿病护理中的应用DOI: 10.1038/s44401-026-00118-8 npj health systemsVolume 3, Issue 1No.229Impact of virtual appointments on referral-to-appointment times for type 2 diabetes patients in Northwest London虚拟预约对伦敦西北部2型糖尿病患者转诊至预约时间的影响DOI: 10.1038/s44401-026-00112-0 npj health systemsVolume 2, Issue 1No.230A large sensor foundation model pretrained on continuous glucose monitor data for diabetes management基于连续血糖监测数据预训练的大型传感器基础模型用于糖尿病管理DOI: 10.1038/s44401-025-00039-y npj health systemsVolume 2, Issue 1No.231Co-design of an intervention to enhance healthcare transition for adolescents and young adults with chronic medical conditions共同设计干预措施以改善患有慢性疾病的青少年和年轻成人的医疗过渡DOI: 10.1038/s44401-025-00041-4 South Dakota journal of medicineVolume 79, Issue 6No.232Clostridium innocuum Bacteremia: Case Report and Systematic Review无害梭菌菌血症：病例报告与系统综述https://pubmed.ncbi.nlm.nih.gov/42527363 Journal of diabetes research IF: 03.400Volume 2026, Issue 1No.233A Qualitative Exploration of the Support Needs of Individuals With Type 2 Diabetes and Disordered Eating Behaviours2型糖尿病合并饮食行为紊乱患者支持需求的定性探索DOI: 10.1155/jdr/7718760 Pain management nursing IF: 02.100Ahead of Print.No.234Influencing Factors and Stability of Self-reported and Observational Pain Scales in Poststroke Patients: A Cross-sectional Study卒中患者自我报告与观察性疼痛量表的影响因素及稳定性：一项横断面研究DOI: 10.1016/j.pmn.2026.07.006 Zhonghua erke zazhiVolume 64, Issue 8No.235[A case report of infantile autoimmune diabetes caused by RNU4ATAC variation][RNU4ATAC变异致婴儿自身免疫性糖尿病一例报告]DOI: 10.3760/cma.j.cn112140-20260424-00347 Heart IF: 04.400Ahead of Print.No.236Diabetes as cardiovascular disease: why the 2026 National Institute for Health and Care Excellence (NICE) Guideline 28 matters to cardiologists糖尿病作为心血管疾病：为何2026年英国国家健康与临床优化研究所（NICE）第28号指南对心脏病学家至关重要DOI: 10.1136/heartjnl-2026-328237 J Immunother Cancer IF: 10.600Volume 14, Issue 7No.237CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironmentCXCR2介导的前列腺癌细胞与免疫抑制性肿瘤微环境之间的代谢相互作用DOI: 10.1136/jitc-2025-014725 Exp Clin Endocrinol Diabetes IF: 01.700Ahead of Print.No.238Position Paper of the German Diabetes Association, German Society of Angiology and Vascular Medicine, German Society for Vascular Surgery and Vascular Medicine and German Society for Interventional Radiology and Minimally Invasive Therapy on the Diagnosis and Treatment of Peripheral Arterial Occlusive Disease in Diabetes Mellitus德国糖尿病协会、德国血管学与血管医学学会、德国血管外科与血管医学学会及德国介入放射学与微创治疗学会关于糖尿病外周动脉闭塞性疾病诊断与治疗的立场声明DOI: 10.1055/a-2766-4074 Diabetes Res Clin Pract IF: 07.400Ahead of Print.No.239Mapping diabetic eye exam non-adherence across urban-rural communities: A GIS-based regional analysis of socioeconomic disadvantage in the Rochester, NY Metropolitan statistical area城乡社区糖尿病眼科检查不依从性的地理映射：基于GIS的纽约州罗切斯特大都市统计区社会经济劣势区域分析DOI: 10.1016/j.diabres.2026.113468 Biochim Biophys Acta Mol Basis Dis IF: 04.200Ahead of Print.No.240Transcriptomic analysis reveals heart failure-related lncRNA LINC00670 as a regulator of colon cancer mesenchymal genes转录组分析揭示心力衰竭相关长链非编码RNA LINC00670作为结肠癌间充质基因的调控因子DOI: 10.1016/j.bbadis.2026.168389 Prog Retin Eye Res IF: 14.700Ahead of Print.No.241Gap Junctions Form Bridges between Bench Studies and Clinical Ophthalmology缝隙连接在基础研究与临床眼科之间架起桥梁DOI: 10.1016/j.preteyeres.2026.101505 The journal of pain IF: 04.000Ahead of Print.No.242Social Determinants of Health as Predictors of Latent Symptom Clusters in Patients Undergoing Maintenance Hemodialysis: A Secondary Analysis of the HOPE Consortium Randomized Trial健康社会决定因素作为维持性血液透析患者潜在症状簇的预测因素：HOPE联盟随机试验的二次分析DOI: 10.1016/j.jpain.2026.106313 JHLT IF: 06.000Ahead of Print.No.243Effect of surgical exposure on outcomes in bilateral lung transplantation: insight from the international multicenter extracorporeal life support (ECLS) in lung transplantation registry手术暴露方式对双侧肺移植结局的影响：来自国际多中心体外生命支持（ECLS）肺移植登记处的见解DOI: 10.1016/j.healun.2026.07.019 Mucosal immunology IF: 07.600Ahead of Print.No.244The club cell circadian clock regulates temporal patterns in leukocyte trafficking in chronic allergic airways disease棒状细胞生物钟调控慢性过敏性气道疾病中白细胞运输的时间模式DOI: 10.1016/j.mucimm.2026.100384 Metabolism IF: 11.900Ahead of Print.No.245Reply to letter to the editor: From metabolic subtypes to preventive decisions in high-risk type 2 diabetes回复编辑来信：从代谢亚型到高危2型糖尿病的预防决策DOI: 10.1016/j.metabol.2026.156719 Annals of epidemiology IF: 03.000Ahead of Print.No.246Incidence and Outcomes of Emergency Medical Service Treated Pulmonary Embolism in Victoria, Australia; A Population-Based Cohort Study澳大利亚维多利亚州急诊医疗服务治疗的肺栓塞的发病率和结局：一项基于人群的队列研究DOI: 10.1016/j.annepidem.2026.110251 Survey of ophthalmology IF: 05.900Ahead of Print.No.247The hard exudate pathway: Biological mechanisms, imaging correlates, and clinical implications硬性渗出通路：生物学机制、影像学关联及临床意义DOI: 10.1016/j.survophthal.2026.07.013 IJC IF: 03.200Ahead of Print.No.248GLIflozins in the prevention of contrast AssocIated NEphropathy: The GLICINE registry格列净类药物预防对比剂相关肾病的GLICINE注册研究DOI: 10.1016/j.ijcard.2026.134700 Free radical biology & medicine IF: 08.200Ahead of Print.No.249VBIT-4 attenuates diabetes-associated cardiac mitochondrial dysfunction and oxidative stress in a mouse model of diabetesVBIT-4减轻糖尿病小鼠模型中心脏线粒体功能障碍和氧化应激DOI: 10.1016/j.freeradbiomed.2026.07.049 Mol Cell Endocrinol IF: 03.600Ahead of Print.No.250Identification of key biomarkers for ferroptosis in diabetic kidney disease using machine learning and WGCNA利用机器学习和WGCNA鉴定糖尿病肾病铁死亡关键生物标志物DOI: 10.1016/j.mce.2026.112877 Int J Biol Macromol IF: 08.500Ahead of Print.No.251A methacrylated carboxymethyl chitosan hydrogel loaded with α-mangostin nano-micelle promotes infected diabetic wound healing involving PPAR-γ modulation负载α-倒捻子素纳米胶束的甲基丙烯酸化羧甲基壳聚糖水凝胶通过PPAR-γ调节促进感染性糖尿病伤口愈合DOI: 10.1016/j.ijbiomac.2026.153778 Int J Biol Macromol IF: 08.500Ahead of Print.No.252Chitosan-based hydrogels for diabetic ulcer therapy: Molecular mechanisms, functional synergies, and future perspectives: A review基于壳聚糖的水凝胶用于糖尿病溃疡治疗：分子机制、功能协同与未来展望DOI: 10.1016/j.ijbiomac.2026.153831 J Small Anim Pract IF: 01.900Ahead of Print.No.253Euthanasia rates and risk factors for euthanasia in dogs diagnosed with diabetes mellitus in Australian primary care practices: 2078 cases (2008-2017)澳大利亚初级诊疗机构中确诊糖尿病犬的安乐死率及风险因素：2078例（2008-2017年）DOI: 10.1111/jsap.70177 Human Reproduction IF: 06.100Ahead of Print.No.254Body fat percentage in relation to semen characteristics, testicular volume, and reproductive hormones: a cross-sectional study体脂率与精液特征、睾丸体积和生殖激素的关系：一项横断面研究DOI: 10.1093/humrep/deag104 Clinical nutrition IF: 07.400Ahead of Print.No.255Nutrient intake, gut inflammation markers, and intestinal permeability in infants aged 6-12 months6-12月龄婴儿营养素摄入、肠道炎症标志物与肠道通透性的关联DOI: 10.1016/j.clnu.2026.106739 General hospital psychiatry IF: 03.700Ahead of Print.No.256AI for mental disorders and diabetes comorbidity management: A scoping review人工智能在精神障碍与糖尿病共病管理中的应用：一项范围综述DOI: 10.1016/j.genhosppsych.2026.06.009 Acta diabetologica IF: 02.900Volume 54, Issue 7No.257Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice新型重组人胰高血糖素样肽-1类似物融合蛋白GW002对CHO重组细胞和BKS-db小鼠的作用DOI: 10.1007/s00592-017-0992-z Current diabetes reviews IF: 01.900Volume 14, Issue 3No.258Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis胰高血糖素样肽-1受体激动剂对全因死亡率和心血管结局的影响：一项荟萃分析DOI: 10.2174/1573399813666170414101450 American family physician IF: 03.500Volume 95, Issue 8No.259Albiglutide (Tanzeum) for Diabetes Mellitus阿必鲁肽（Tanzeum）用于糖尿病治疗https://pubmed.ncbi.nlm.nih.gov/28409609 Diabetes Metab Syndr Obes IF: 03.000Volume 10, Issue No.260Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists胰高血糖素样肽-1受体激动剂在2型糖尿病长期管理中的应用DOI: 10.2147/DMSO.S126763 Diabetes Res Clin Pract IF: 07.400Volume 126, Issue No.261Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials阿必鲁肽治疗2型糖尿病：HARMONY 3期试验的综合安全性分析DOI: 10.1016/j.diabres.2017.02.017 Scand J Gastroenterol IF: 01.700Volume 52, Issue 6-7No.262Bariatric surgery - time to replace with GLP-1?减重手术——是时候用GLP-1替代了吗？DOI: 10.1080/00365521.2017.1293154 Diabetes, obesity & metabolism IF: 05.700Volume 19, Issue 9No.263Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials胰高血糖素样肽-1受体激动剂的安全性问题（胰腺炎、胰腺癌和胆石症）：来自随机对照试验的数据DOI: 10.1111/dom.12926 Advances in therapy IF: 04.000Volume 34, Issue 3No.264The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy药师在2型糖尿病管理中应用胰高血糖素样肽-1受体激动剂作为附加治疗的作用DOI: 10.1007/s12325-017-0491-1 Diabetes, obesity & metabolism IF: 05.700Volume 19, Issue 7No.265Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide2型糖尿病患者使用胰高血糖素样肽-1受体激动剂的治疗模式：度拉糖肽相比每周一次艾塞那肽和利拉鲁肽具有更高的依从性和持久性DOI: 10.1111/dom.12902 Diabetology & metabolic syndrome IF: 03.900Volume 9, Issue No.266Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?将GLP-1受体激动剂分类为基础和餐时是否有依据？DOI: 10.1186/s13098-017-0204-6 The Nurse practitioner IF: 00.900Volume 42, Issue 2No.267Albiglutide for the treatment of type 2 diabetes mellitus阿必鲁肽治疗2型糖尿病DOI: 10.1097/01.NPR.0000488718.72389.5c Clinical pharmacokinetics IF: 04.000Volume 56, Issue 7No.268Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide阿必鲁肽的临床药代动力学和药效学DOI: 10.1007/s40262-016-0499-8 Diabetes, obesity & metabolism IF: 05.700Volume 19, Issue 4No.269Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis胰高血糖素样肽-1受体激动剂在2型糖尿病中的有效性和安全性：系统评价与混合治疗比较分析DOI: 10.1111/dom.12849 Ther Adv Drug Saf IF: 03.400Volume 7, Issue 6No.270Albiglutide-induced pancreatitis阿必鲁肽诱发的胰腺炎DOI: 10.1177/2042098616667352 Diabetes, obesity & metabolism IF: 05.700Volume 19, Issue 3No.271Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials胰高血糖素样肽-1受体激动剂临床试验中恶心、呕吐和腹泻不良事件发生率的系统分析DOI: 10.1111/dom.12824 Curr Med Res Opin IF: 02.200Volume 33, Issue 3No.272Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs阿必鲁肽，一种每周一次的GLP-1受体激动剂，在1年内改善日本2型糖尿病患者血糖参数DOI: 10.1080/03007995.2016.1261817 The annals of pharmacotherapy IF: 02.300Volume 50, Issue 12No.273Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders胰高血糖素样肽-1受体激动剂在心脏疾病中的应用DOI: 10.1177/1060028016663218 Current diabetes report IF: 06.400Volume 16, Issue 12No.274A Plethora of GLP-1 Agonists: Decisions About What to Use and When众多GLP-1受体激动剂：如何选择及何时使用DOI: 10.1007/s11892-016-0823-6 Expert Opin Biol Ther IF: 04.000Volume 16, Issue 12No.275Albiglutide: a unique GLP-1 receptor agonist阿必鲁肽：一种独特的GLP-1受体激动剂DOI: 10.1080/14712598.2016.1240780 SAGE open medicine IF: 02.100Volume 4, Issue No.276An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease二肽基肽酶-4抑制剂在2型糖尿病合并中重度慢性肾脏病患者中有效性和耐受性的最新系统评价与荟萃分析DOI: 10.1177/2050312116659090 Pharmacotherapy IF: 03.400Volume 36, Issue 9No.277Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus胰高血糖素样肽-1受体激动剂在1型糖尿病管理中的辅助作用DOI: 10.1002/phar.1804 Drugs of today IF: 01.800Volume 52, Issue 6No.278American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA)美国糖尿病协会第76届科学会议（2016年6月10-14日，美国路易斯安那州新奥尔良）DOI: 10.1358/dot.2016.52.6.2516437 Int J Clin Pract IF: 02.400Volume 70, Issue 8No.279Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials每周一次胰高血糖素样肽-1受体激动剂与艾塞那肽和利拉鲁肽在2型糖尿病中的有效性和安全性：随机对照试验的系统评价DOI: 10.1111/ijcp.12847 Clinical pharmacology IF: 02.500Volume 8, Issue No.280The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies肾功能不全时2型糖尿病的治疗：关于新型疗法应了解的内容DOI: 10.2147/CPAA.S82008 Microcirculation IF: 02.000Volume 33microcirculation, Issue 6, Page e70066-e70080No.281Plantar Foot Microvascular Reactivity and Oxygenation in Type 2 Diabetes and Peripheral Artery Disease: An Exploratory Study2型糖尿病和外周动脉疾病患者足底微血管反应性与氧合：一项探索性研究DOI: 10.1111/micc.70078 ImmunoHorizonsVolume 10, Issue 7No.282Absence of insulin receptor substrate 2 (IRS2) in myeloid cells results in enhanced hypoxia-induced remodeling of the pulmonary vasculature and heart with modest effects on allergic lung inflammation髓系细胞中胰岛素受体底物2缺失导致缺氧诱导的肺血管和心脏重塑增强，但对过敏性肺部炎症影响较小DOI: 10.1093/immhor/vlag028 South Dakota journal of medicineVolume 79, Issue 3No.283Shifting Trends in Early-Onset Colorectal Cancer in South Dakota: A Focus on Population Incidence Patterns南达科他州早发性结直肠癌的趋势转变：关注人群发病率模式https://pubmed.ncbi.nlm.nih.gov/42525801 Journal of neuroendocrinology IF: 04.100Volume 38, Issue 8No.284Hyponatremia correction is associated with increased brain-derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double-blind, placebo-controlled, crossover trial低钠血症纠正与脑源性神经营养因子水平升高相关：一项随机、双盲、安慰剂对照交叉试验的初步二次分析DOI: 10.1111/jne.70238 Curr Top Med Chem IF: 03.300Ahead of Print.No.285Bioisosteric Replacement of Carboxylic Acids in PPAR Agonists: A Mini ReviewPPAR激动剂中羧酸的生物电子等排替代：小型综述DOI: 10.2174/0115680266466273260722130035 Liver international IF: 05.200Volume 46, Issue 9No.286Gene-Based Clustering Identifies QSOX1 and IL1RAP as Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease基于基因聚类分析鉴定QSOX1和IL1RAP为代谢功能障碍相关脂肪性肝病的生物标志物DOI: 10.1111/liv.70823 Circulation Research IF: 16.200Ahead of Print.No.287Methylmalonate Overload Despite Glycemic Control Drives Diabetic Heart Damage血糖控制下甲基丙二酸过量驱动糖尿病心脏损伤DOI: 10.1161/CIRCRESAHA.125.327192 JMIR formative research IF: 02.100Volume 10, Issue No.288Clinical Decision Support for Digital Dietary Counseling Under GLP-1 Receptor Agonist Therapy: Convergent Mixed Methods Usability and Treatment Satisfaction Pilot Study of the Personalized Nutrition AdvisorGLP-1受体激动剂治疗下数字饮食咨询的临床决策支持：个性化营养顾问的聚合混合方法可用性与治疗满意度试点研究DOI: 10.2196/81112 Hum Vaccin Immunother IF: 03.500Volume 22, Issue 1No.289Influenza vaccination associates with reduced risk of incident ischemic stroke among older adults with diabetes: A population-based retrospective cohort study流感疫苗接种与老年糖尿病患者新发缺血性卒中风险降低相关：一项基于人群的回顾性队列研究DOI: 10.1080/21645515.2026.2697144 Clin Chem Lab Med IF: 03.700Ahead of Print.No.290Proposed laboratory diagnostic workflow in the Italian national screening program for type 1 diabetes意大利1型糖尿病国家筛查计划中拟议的实验室诊断工作流程DOI: 10.1515/cclm-2026-0536 Transl Behav Med IF: 03.000Volume 16, Issue 1No.291Designing men's health fairs: community-guided strategies设计男性健康博览会：社区引导策略DOI: 10.1093/tbm/ibag050 The annals of pharmacotherapy IF: 02.300Ahead of Print.No.292Impact on Vulnerable Populations After Discontinuation of Continuous Glucose Monitoring in Patients With Type 2 Diabetes2型糖尿病患者停止持续葡萄糖监测对弱势人群的影响DOI: 10.1177/10600280261470410 Endocrinol Diabetes Metab IF: 02.600Volume 9, Issue 5No.293Comment on 'Clinical Presentation and Early Outcomes of Congenital Endocrine Salt-Wasting Syndromes Unrelated to 21-Hydroxylase Deficiency'对《非21-羟化酶缺乏所致先天性内分泌性盐耗综合征的临床表现与早期结局》一文的评论DOI: 10.1002/edm2.70299 Aust N Z J Obstet Gynaecol IF: 01.700Volume 66, Issue 4No.294Outcomes for Women With Diabetes at Late Preterm Gestation Who Received Antenatal Corticosteroids: A Population-Based Cohort Study妊娠晚期早产合并糖尿病女性接受产前皮质类固醇治疗的结果：一项基于人群的队列研究DOI: 10.1111/ajo.70164 Endocrinol Diabetes Metab IF: 02.600Volume 9, Issue 5No.295Reassessing Radioactive Iodine Use After Thyroidectomy in Low-Risk Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis重新评估低风险分化型甲状腺癌甲状腺切除术后放射性碘的使用：系统综述和荟萃分析DOI: 10.1002/edm2.70293 Liver international IF: 05.200Volume 46, Issue 9No.296Autophagy in MASLD: A Metabolic and Precision Medicine Perspective自噬在代谢相关脂肪性肝病中的代谢与精准医学视角DOI: 10.1111/liv.70816 Experimental dermatology IF: 03.100Volume 35, Issue 8No.297Minoxidil Sulfate Regulates JAK/STAT Signalling and Mitochondrial Function in Alopecia Areata硫酸米诺地尔调节斑秃中的JAK/STAT信号和线粒体功能DOI: 10.1111/exd.70335 Diabetes & metabolism journal IF: 08.500Ahead of Print.No.298Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study双重SGLT1和SGLT2抑制剂JP-2266在2型糖尿病中的有效性和安全性：一项随机、双盲、安慰剂对照的2期研究DOI: 10.4093/dmj.2025.1152 CNS spectrums IF: 04.100Ahead of Print.No.299Pharmacologic Modulation of Orexin Signaling: Impact on Glucose-Insulin Homeostasis and Potential Mechanism of Antidepressant Action食欲素信号通路的药理学调节：对葡萄糖-胰岛素稳态的影响及抗抑郁作用的潜在机制DOI: 10.1017/S1092852926101126 Current drug safety IF: 01.100Ahead of Print.No.300Clinical Experience with Quintuple Non-Insulin Drug Therapy in Suboptimally Controlled Type 2 Diabetes五联非胰岛素药物治疗在血糖控制不佳的2型糖尿病中的临床经验DOI: 10.2174/0115748863485481260722093116 Current pharmaceutical design IF: 02.800Ahead of Print.No.301Nutritional Adjuvants in Diabetes: Biotin and Chromium Picolinate as Emerging Therapeutic Agents糖尿病营养辅助剂：生物素和吡啶甲酸铬作为新兴治疗药物DOI: 10.2174/0113816128456434260713163014 Diab Vasc Dis Res IF: 03.000Volume 23, Issue 4No.302Skin autofluorescence may be a biomarker associated suboptimal glycemic control in pregnant women with gestational diabetes mellitus皮肤自发荧光可能是妊娠期糖尿病孕妇血糖控制不佳的生物标志物DOI: 10.1177/14791641251398558 Cancer biology & therapy IF: 04.600Volume 27, Issue 1No.303Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics胰岛素抵抗与癌症的分子相互作用：单克隆抗体治疗的进展DOI: 10.1080/15384047.2026.2708386 British journal of pharmacology IF: 07.700Ahead of Print.No.304Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin-dependent protein kinase IIδ in a murine model of acute doxorubicin-related cardiotoxicity抑制晚期钠电流可预防急性阿霉素相关心脏毒性小鼠模型中钙/钙调蛋白依赖性蛋白激酶IIδ的病理性过度激活DOI: 10.1111/bph.70561 Advanced healthcare materials IF: 09.600Ahead of Print.No.305Conjugated Porphyrin Polymer With Superior Charge Transfer for Photodynamic-Immunomodulatory Prevention of CIED Infection in Diabetes具有优异电荷转移的共轭卟啉聚合物用于糖尿病中CIED感染的光动力-免疫调节预防DOI: 10.1002/adhm.71482 Clinical Cardiology IF: 02.300Volume 49, Issue 8No.306Dynamic Co-Evolution of Obesity-Metabolic-Inflammatory for Cardiovascular Disease Risk Stratification in Middle-Aged and Older Adults: A Data-Driven Joint Trajectory Analysis肥胖-代谢-炎症动态共演化对中老年人心血管疾病风险分层：一项数据驱动的联合轨迹分析DOI: 10.1002/clc.70429 Renal failure IF: 03.000Volume 48, Issue 1No.307Association between estimated glucose disposal rate and nephrolithiasis: a propensity score matching study in US adults: results from the National Health and Nutrition Examination Survey 2011-2020估计葡萄糖利用率与肾结石的关联：一项基于美国成年人的倾向评分匹配研究——2011-2020年国家健康与营养调查结果DOI: 10.1080/0886022X.2026.2684346 Cardiovascular Drugs and Therapy IF: 03.100Ahead of Print.No.308Finerenone After FINE-ONE and CONFIDENCE: Updating the Cardiorenal–Metabolic Treatment Paradigm Beyond Type 2 Diabetes非奈利酮在FINE-ONE和CONFIDENCE研究之后：更新2型糖尿病以外的心肾代谢治疗模式DOI: 10.1007/s10557-026-07924-0 219 Diabetes Mellitus(DM) 糖尿病 71 Insulin 胰岛素 55 Obesity 肥胖症 40 Type 2 diabetes mellitus(T2DM) 2型糖尿病 28 Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RA) 胰高血糖素样肽-1受体激动剂 25 Albiglutide 阿必鲁肽 22 Hypoglycemic Agents 降糖药 17 Liraglutide 利拉鲁肽 15 Dulaglutide 度拉糖肽 15 Exenatide 艾塞那肽 13 Diabetic Retinopathy 糖尿病视网膜病 10 Metformin 二甲双胍 10 Lixisenatide 利司那肽 10 Diabetic Kidney Disease(DKD) 糖尿病肾脏病 9 Metabolic Syndrome 代谢综合征 8 Type 1 diabetes mellitus(T1DM) 1型糖尿病 8 Semaglutide 司美格鲁肽 7 Sodium-Glucose Transporter 2 Inhibitors(SGLT-2i) 钠-葡萄糖协同转运蛋白2抑制剂 6 Diabetic Foot 糖尿病足 6 Empagliflozin 恩格列净 4 Diabetic acidosis 糖尿病性酸中毒 4 Sitagliptin 西他列汀 3 Vildagliptin 维格列汀 3 Dapagliflozin 达格列净 2 Linagliptin 利格列汀 2 Canagliflozin 卡格列净 2 gamma-Aminobutyric Acid(GABA) γ-氨基丁酸 2 Gestational Diabetes Mellitus(GDM) 妊娠糖尿病 1 Dipeptidyl-Peptidase IV Inhibitors(DPP-4i) 二肽基肽酶-4抑制剂 1 Saxagliptin 沙格列汀 1 Gabapentin 加巴喷丁 1 Pregabalin 普瑞巴林 1 Diabetic Peripheral Neuropathy(PDN) 糖尿病周围神经病变 1 Diabetic Cardiomyopathies 糖尿病心肌病 1 Tirzepatide 替尔泊肽 1 Diabetic Neuropathies 糖尿病性神经病变 编辑：韩玉莲 审校：韩玉莲